Annual Report 2023 RHÖN-KLINIKUM AG

OUR MISSION Our Mission RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. We offer excellent medical care with a direct tie-in to universities and research facilities. With our campus approach we set standards for cross-sector medical, therapeutic and nursing care – and not just in rural areas. Our five maximum- and intermediate-care hospital sites – Campus Bad Neustadt, Klinikum Frankfurt (Oder), Giessen and Marburg University Hospitals as well as Zentralklinik Bad Berka – are attractive employers and training centres. RHÖN is a modern and diverse Company. Diversity is our strength. People from over 70 nations work for our Company. Our activities are defined by common values such as responsibility, tolerance, respect, integrity, openness and togetherness. Sustainability is an essential part of our identity. It reflects how we create a healthy environment for our patients, employees, business partners and investors. At the same time, it enables us to safeguard our success on a sustainable basis. RHÖN-KLINIKUM AG | Annual Report 2023 1

LETTER TO SHAREHOLDERS For the employees in Giessen and Marburg, a job-protection-and-relief collective agreement recognising UKGM as an attractive employer and recruiter in the area of university medicine was also concluded. This is at once a sign of confidence, a pledge of trust and a mandate that we will honour together with the employees. Moreover, protection from redundancies and outsourcing now also applies to the roughly 300 employees of UKGM Service GmbH. Our goals and strengths We are steadfastly pursuing our strategic objectives. For over 50 years, these have been reframed and revised time and again, something that has become more important than ever given the rapidly unfolding developments on the healthcare market. And it confirms that we are on the right path. Firstly, our hospitals will continue to focus on their core activities, i. e. on inpatient treatment services, with the goal of being able to provide our patients with cutting-edge medical care at all sites. We daily commit ourselves to ensuring that they feel safe in our hands, receive outstanding medical, nursing as well as therapeutic care, and are happy with our services. Ensuring that this remains the case at all times is our top priority. This is supported by our standards and expectations for medical excellence, a comprehensive quality management programme and close collaboration with our partners from the Asklepios Group. Secondly, above and beyond that we are investing in the expansion of outpatient care so that we can offer patients alternatives to an inpatient hospital stay meeting a high quality of medical care without having to sacrifice the standards of a treatment at a hospital. These alternatives are being made possible thanks to the interdisciplinary competence, high level of medical technology and the possibility of enabling an inpatient treatment right next door should the urgent need arise. Since January of this year, the Catalogue of Outpatient Operations and Procedures Substituting for Inpatient Care (AOP Catalogue) has included an additional 171 operation and procedure codes (OPS). That puts the total at 3,312 services which can be provided in hospitals on an outpatient basis. The hybrid DRGs adopted at the end of last year also broaden the scope for outpatient procedures in the hospital yet further. Last year, further outpatient offerings were added at all our sites. In Marburg, for example, we introduced an interdisciplinary thoraxoncological consultation. At the Outpatient Operation Centre (AOZ) of Bad Neustadt we established a new operating theatre enabling the implanting of cardiac pacemakers and defibrillators. At Klinikum Frankfurt (Oder) there is a new innovative point of contact for children and youth suffering from nervous system disorders or diseases that combines outpatient and inpatient care. Our hospital Zentralklinik Bad Berka modernised and expanded its outpatient diagnostic services, including in the area of laboratory services. Since October 2023, the University Hospital of Giessen has been collaborating with the neurology department of Lahn-Dill-Kliniken in Wetzlar, which in special consultations transfers outpatients to Giessen. Optimising our processes is another strategic area of action. In addition to ongoing efforts to improve our clinical processes, the focus here is in particular on the purchasing and IT areas. Improvements in margins that can be achieved thanks to size advantages in purchasing as well as positive economies of scale help keep our Company on a sound footing. We have defined standards for processes or medical devices that are adopted at all our facilities across all sites. RHÖN-KLINIKUM AG | Annual Report 2023 3

LETTER TO SHAREHOLDERS Responsibility, sustainability, integrity, trust and loyalty: those are values to which our Company and its employees have always felt committed right from the start. Each day we provide medical services to the highest standards and create a healthy environment for our patients, business partners, investors and our employees. More than 18,000 people are employed at RHÖN-KLINIKUM AG. Roughly 1,700 people complete their training at our hospital-affiliated schools in nursing, medical, commercial and technical professions. For us, retaining our qualified employees and recruiting new staff members is hugely important. We offer good opportunities for personal advancement and are continuously investing in initial and ongoing training, healthcare management and attractive work-life services for our staff. RHÖN is a modern, open and diverse Company. In science and research we work across borders, and at our hospitals we collaborate in multi-cultural teams. At the same time, demand for employees from the nursing and physician professions presents us with a particular challenge. Given the shortage of nursing staff seen nationally, we urgently need qualified professionals from abroad. And that is why we have stepped up our recruiting measures and international contacts to recruit nursing staff in over twenty countries and are doing everything we can to enable their good integration. Dear Shareholders, Entrepreneurial freedom, dynamic development and change are the things that have characterised RHÖN, and that for 50 years now. We have always proven how efficient we are. That, too, is something that makes us stand out and is part of our DNA. Today, yesterday and tomorrow. We are also ready to take on our future challenges. Particularly in times of great uncertainty at home and abroad, our Company undoubtedly demonstrates historical continuity, as well as new beginnings and future viability – we act responsibly and professionally. That is something we have always shown. At this time my special thanks goes to our employees. We as the Board of Management are aware how challenging and demanding your tasks often are. That deserves our heartfelt recognition. I thank you, dear Shareholders, for your loyalty and the trust you place in us. Yours sincerely, Prof. Dr Tobias Kaltenbach Chairman of the Board of Management RHÖN-KLINIKUM Aktiengesellschaft Bad Neustadt a. d. Saale, March 2024 RHÖN-KLINIKUM AG | Annual Report 2023 5

REPORT OF THE SUPERVISORY BOARD Cooperation between the Supervisory Board and the Board of Management During financial year 2023, the Supervisory Board also examined on an ongoing basis and in detail the situation and development of the Company, performing fully, and with the requisite care, the duties incumbent on it by law, the Articles of Association and the Terms of Reference. These include continuously monitoring management activity and regularly advising the Board of Man- agement on directing the Company. In performing its duties, the Supervisory Board was at all times guided by the decisive principles of appropriateness, compliance with legal provisions, expediency and efficiency. Observance of these principles by the Board of Management was monitored by a regular review of the Company’s general organisation and verifying the instruments used for internal risk control. The Supervisory Board was involved in fundamental and important decisions taken by the Board of Management of RHÖN-KLINIKUM Aktiengesellschaft. The Board of Management complied with its duties to keep us informed, doing so on a timely basis and comprehensively both in written form and orally. Docu- ments and records of relevance for decisions were provided to us in good time prior to the respective consultations and meetings. We acknowledged the reporting and the information submitted by the Board of Management regarding strategic and operative business performance, compliance issues as well as risks and risk management, and reviewed the same for plausibility and compre- hensibility, advised the Board of Management and discussed issues of business performance thoroughly with the Board of Manage- ment and also scrutinised the same. As chairman of the Supervisory Board, I also personally engaged in a regular exchange of information and ideas with all members of the Board of Management – also between meetings held by the corporate bodies – and was kept thoroughly informed at all times about material developments and current business transactions. We thoroughly discussed the resolution proposals made by the Board of Management in the Supervisory Board committee responsible for the respective items and/or the Supervisory Board plenary session and, to the extent required by law, the Articles of Association and the Terms of Reference, gave our opinion on the same after a careful review. Where required in the case of particu- larly pressing and time-critical business matters, the Supervisory Board, or, as the case may be, the competent committee also adopted resolutions by voting in written form. Work of the Supervisory Board in the plenary session In financial year 2023, a total of five meetings of the Supervisory Board plenary session were held (four ordinary meetings and one extraordinary meeting); moreover, four written resolutions were adopted in the writing voting procedure. The members of the Board of Management attended all meetings of the Supervisory Board except where agenda items relating to internal matters of the Supervisory Board and matters pertaining to the Board of Management were discussed. The meetings of the Supervisory Board plenary session were held as in-person meetings, with the possibility of joining the meetings virtually (so-called hybrid meeting). At the meetings of the Supervisory Board the plenary session, based on detailed reports of the Board of Management on current develop- ments, strategic issues and the financial position of the Group, as well as based on the written reports and presentations by the Board of Management, regularly deliberated together with the Board of Management on the net assets, financial position and results of operations, the trend in revenues and earnings, the performance data, key figures and human resources of the Company and Group as well as of the individual Group subsidiaries. The Supervisory Board was informed of deviations of business performance from the targets. The Board of Management moreover informed on current developments in healthcare policy, the healthcare environment, healthcare legislation and their impact on the Group as well as on the competitive situation. In particular, the planned hospital reform and its significance for the RHÖN-KLINIKUM Group was thoroughly discussed. The Supervisory Board moreover, together with the Board of Management, examined the sharp rises in costs of energy, commodities and materials, as well as the repercussions of the COVID-19 pandemic for the business development and the hospitals of the RHÖN-KLINIKUM Group. Another focus of attention of the supervisory activity in financial year 2023 was on the deliberation and discussions relating to the situation at UKGM. At an extraordinary Supervisory Board meeting in February 2023, the Supervisory Board, after a thorough discussion, approved the conclusion of the – already mentioned – “White Paper Plus” with the Federal State of Hesse and the universities in Giessen and Marburg. In the further course of the year, the Supervisory Board then regularly examined the stage of implementation of the “White Paper Plus”, in particular the invest- ment obligations agreed therein. Moreover, the Supervisory Board discussed the strike actions taken at UKGM in early 2023, their economic impact and the relief collective agreement. RHÖN-KLINIKUM AG | Annual Report 2023 7

The Audit Committee notably was responsible for review and pre- liminary consultation for the RHÖN-KLINIKUM Aktiengesellschaft consolidated annual financial statements for financial year 2022. The Audit Committee assessed the independence of KPMG designated as statutory auditor to audit the consolidated financial statements and the Group management report as well as the annual financial statements and the management report for finan- cial year 2023 and to conduct the review of the half-year financial report, obtained the statement regarding the auditor’s indepen- dence, recommended to the plenary session of the Supervisory Board a proposal for the election of the auditor to be submitted to the Annual General Meeting and – after the election – issued the statutory auditor with the audit assignment and concluded with it a fee agreement for the same. The Audit Committee also defined the areas of emphasis of the audit of the 2023 annual financial statements that were to be considered by the statutory auditor beyond the statutory audit scope. Questions of fundamental importance relating to accounting, corporate planning, the capital base, the monitoring of the accounting process, as well as the effectiveness of the internal controlling system, risk management system (including special business risks), and the internal audit system were discussed with the Board of Management and in some cases also with the statutory auditor. The interim reports were thoroughly discussed on a regular basis with the Board of Management prior to their publication, as well as the half-year financial report with the Board of Management and in the presence of the statutory auditor giving due regard to the review by the latter. The Group controlling report on performance and finance controlling submitted quarterly, which forms part of our risk management system, was thoroughly discussed in each case with the Board of Management. Here, the development of service volumes and earnings of the Group and of the individual Group hospitals was also analysed, scrutinised and discussed with the Board of Management, also with regard to deviations from targets. The Audit Committee kept itself regularly informed about the activity of the Internal Audit and Compliance departments. REPORT OF THE SUPERVISORY BOARD Corporate Governance and issuance of Declaration of Compliance Pursuant to section 161 of the German Stock Corporation Act (AktG), the management board and supervisory board of a German exchange-listed stock corporation are required to state each year in a Declaration of Compliance to what extent the company complies with the recommendations of the German Corporate Governance Code (GCGC) and in what respects it deviates from such recommendations. The Board of Management and the Supervisory Board in December 2023 submitted such Declaration of Compliance pursuant to section 161 AktG – prepared by the Audit Committee – which is made perma- nently available on the website of RHÖN-KLINIKUM Aktiengesellschaft. The Supervisory Board reports on corporate governance jointly with the Board of Management in the Declaration on Corporate Governance likewise published on the website. The Remuneration Report for the Board of Management as well as the remuneration scheme for the members of the Board of Manage- ment approved by the Annual General Meeting on 9 June 2021 is also publicly available on the website. Examination and approval of the 2023 financial statements The Board of Management adopted the financial statements of the Company and the management report for the year ended 31 December 2023 in accordance with the provisions of the German Commercial Code (HGB), while the consolidated financial statements as at 31 December 2023 and Group management report for financial year 2023 were adopted pursuant to section 315e HGB in accordance with the principles set out in the Inter- national Financial Reporting Standards (IFRS). The auditor, KPMG, examined the annual financial statements and the management report of the Company for financial year 2023 as well as the consolidated financial statements and Group management report for financial year 2023. The statutory auditor issued an unqualified auditor’s report in each case. The financial statements and management report of the Company, the consolidated financial statements and Group management report as well as the reports of the auditor KPMG as statutory auditor on the result of its audit were received by all members of the Super- visory Board together with the Board of Management’s proposal for the appropriation of the net distributable profit for the year. These documents were examined by the Supervisory Board and exten- sively discussed by the Audit Committee and by the Supervisory Board with representatives of the auditor at the respective balance sheet meetings. As part of the audit, the Audit Committee and the Supervisory Board examined both the accounting findings and the procedures and processes relating to the accounting findings and RHÖN-KLINIKUM AG | Annual Report 2023 9

REPORT OF THE SUPERVISORY BOARD The personal details of the members of the Supervisory Board in 2023 are set out in the Notes to the consolidated financial statements. The section also provides information on the professional qualifications of the Supervisory Board members as well as their other mandates. The organisational structure of the Supervisory Board and the composition of the committees during the past financial year are set out in the overview provided following this Report. The Supervisory Board thanks the Board of Management, all employees of the Group as well as the employee representatives of all Group companies for all their tremendous commitment and work that made financial year 2023 such a success. The Supervisory Board Dr Jan Liersch (Chairman) Bad Neustadt a. d. Saale, 27 March 2024 Composition of the Supervisory Board and changes in the Supervisory Board In accordance with the requirements of the Co-Determination Act ( MitBestG), the Supervisory Board of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 10 (1) MitBestG is comprised of 16 members. Eight Supervisory Board members are elected by the shareholders and eight Supervisory Board members by the employees. In accordance with section 96 (2) AktG, at least 30 per cent of the Supervisory Board is to be made up of women and at least 30 per cent of men, which – relative to the entire Supervisory Board – corresponds to at least five seats. There were no personnel changes on the Board of Management in financial year 2023. However, in September 2023 Mr. Georg Schulze notified the chairman of the Supervisory Board that he was resigning from his Supervisory Board mandate with effect from the expiry of 31 December 2023. By resolution of 7 December 2023, the Local Court of Schweinfurt then appointed Mr. Stefan Röhrhoff as member of the Supervisory Board of the Company to replace Mr. Georg Schulze with effect from 1 January 2024. Furthermore, Mr. Kai Hankeln notified the Company on 13 February 2024 that he was resigning his mandate as member of the Supervisory Board of the Company with immediate effect and left the Supervisory Board with effect from 13 February 2024. The Supervisory Board therefore resolved on 21 February 2024 on the recommendation of the Nomination Committee to propose Mr. Joachim Gemmel, Chief Executive Officer (CEO) of Asklepios Kliniken GmbH & Co. KGaA, Hamburg, for the election to be held at the 2024 Annual General Meeting, to succeed Mr. Hankeln as member of the Supervisory Board of RHÖN- KLINIKUM Aktiengesellschaft for the remaining term of office. For the period until then, the Local Court of Schweinfurt, by Decision of 14 March 2024 issued on the application by the Board of Management based on a corresponding proposal of the Supervisory Board, appointed Mr. Joachim Gemmel as member of the Supervisory Board of the Company. RHÖN-KLINIKUM AG | Annual Report 2023 11

REPORT OF THE SUPERVISORY BOARD 2. Composition of the standing committees Personnel Affairs Committee Dr Jan Liersch, Chairman Nomination Committee Dr Jan Liersch, Chairman Members Number of meetings: 2 Members Peter Ducke Kai Hankeln Dr Jan Liersch Dr Thomas Pillukat Attendance 2 2 2 2 100% 100% 100% 100% Kai Hankeln Dr Jan Liersch Hafid Rifi Number of meetings: 0 Attendance Mediation Committee Dr Jan Liersch, Chairman Committee for Decisions on Related-Party Transactions Dr Jan Liersch, Chairman Members Number of meetings: 0 Members Attendance Number of meetings: 0 Attendance Kai Hankeln Dr Jan Liersch Dr Thomas Pillukat Georg Schulze Audit Committee Hafid Rifi, Chairman Members Peter Berghöfer Regina Dickey Prof. Dr Leopold Eberhart Irmtraut Gürkan Dr Jan Liersch Hafid Rifi Irmtraut Gürkan Dr Jan Liersch Oliver Salomon Georg Schulze Number of meetings: 4 Attendance 4 4 4 4 4 4 100% 100% 100% 100% 100% 100% RHÖN-KLINIKUM AG | Annual Report 2023 13

THE RHÖN-KLINIKUM SHARE Performance of stock markets The German leading index DAX® recorded an increase of 20.3 per cent in 2023 to close the stock market year at 16,752 points. Other comparison indices likewise put in a disproportionately strong performance against the RHÖN share. The second-tier index SDAX® rose by 17.1 per cent and closed the stock market year at 13,960 points. During the same period, the European leading index DJ EURO STOXX 50® climbed by 19.2 per cent. By contrast, the benchmark index for European stocks from the healthcare industry, DJ EURO STOXX Healthcare®, like the RHÖN share, recorded a decline. This drop in the benchmark index DJ EURO STOXX Healthcare® compared with the previous year’s closing price was 2.4 per cent. DE0007042301 RHK 167,406,175 66,962,470 01.01.–31.12.2023 01.01.–31.12.2022 10.00 15.25 10.00 31.12.2023 669.62 15.30 16.20 13.00 31.12.2022 1,024.53 RHÖN-KLINIKUM SHARE ISIN Ticker symbol Share capital (€) Number of shares Share prices (€) Closing price High Low Market capitalisation (€ m) Shareholder structure According to the notifications of voting rights made pursuant to section 33 et seq. of the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG), the shareholder structure of RHÖN-KLINIKUM AG is as follows. SHAREHOLDER STRUCTURE OF RHÖN-KLINIKUM AG in % C: 0.04 B: 6.58 A: AMR Holding GmbH, Dr Bernard große Broermann B: Free float C: Treasury stock A: 93.38 As at 31 December 2023 (on the basis of the most recent notification of voting rights to the company) RHÖN-KLINIKUM AG | Annual Report 2023 15

Corporate Social Responsibility Report Sustainability management and organisation Patients Employees Compliance Data protection Environmental protection Supplier management 19 34 40 46 47 48 53 RHÖN-KLINIKUM AG | Annual Report 2023 17

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Corporate Social Responsibility Report SUSTAINABILITY MANAGEMENT AND ORGANISATION For us, sustainability is firmly established as part of our corporate strategy. Environmental protection, social matters and governance are just as important to us as issues from the medical world. Sustainability as an integral part of our corporate strategy | We do not understand sustainability as being just something that is “nice to have” but rather as being an integral part of the corporate strategy of RHÖN-KLINIKUM AG. That is why all members of the Board of Management deal with this in their work as they promote the con- tinuous enhancement of all aspects of this subject within the Company. As a healthcare group, we embrace our medical, ecological, social and entrepreneurial responsibility. | Another way in which we define ourselves and the goals we strive to achieve is by holding each employee of RHÖN KLINIKUM AG to act with integrity at all times. In this regard the principles of conduct of our Corporate Code set out both the conduct of all employees amongst themselves and respectful dealings with our patients and business partners. In addition, Group-level works council agreements between the Board of Management and the employee representatives ensure the personal integrity of our employees also in their relationship with external entities. Transformation concept | In financial year 2023, we were thoroughly engaged with the subject of sustainability. In this context, environmental protection is taking up an increasingly important role for our Company. We see the most significant challenge in the issues of supplying sustainable energy to our hospital sites. That is why we created a transformation concept in 2023. It sets out a plan of action outlining specific options for the substitution of conventional energy sources and energy conservation potential. Furthermore, CO2 reduction paths for the individual facilities were also identified. These measures lay out the potential roadmap for our environmental strategy. Sustainability strategy (ESG strategy) | Our sustainability strategy is built on the three pillars: environ- mental, social and governance. It is further developed and expanded on an ongoing basis. Overall responsibility lies with the Board of Management. Operative implementation is the responsibility of the individual sites. The Investor Relations & Sustainability division oversees the key objectives. | In the environmental area, RHÖN-KLINIKUM AG’s goal is to achieve CO2 reductions (Scope 1 and 2) of up to 42,900 tonnes by 2030. This roughly corresponds to half of Scope 1 and 2 emissions of the base year 2022. By financial year 2040, RHÖN-KLINIKUM AG is looking to achieve greenhouse gas neutrality in Scope 1 and 2 emissions. To do this, the Company is committed to a steadily expanding and more sustainable supply of energy from regenerative sources, more sustainable heat supply and advances in technology. In particular photovoltaic systems, but also wind power, are important pillars of the CO2 reduction path ahead. A further conservation measure we have identified is the gradual expansion of LED lighting for our buildings. We are also planning to gradually switch to the purchase of electricity from 100 per cent renewable sources (green electricity, Scope 2). | We also believe waste avoidance makes a significant contribu- tion to protecting the environment. By 2030, we are thus looking to reduce the amount of waste in relation to patient numbers. RHÖN-KLINIKUM AG | Annual Report 2023 19 19

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation be environmentally sustainable and taxonomy-aligned where such activities contribute substantially to one or more environmental objectives, do not significantly harm any of the other environ mental objectives, and meet the requirements for compliance with the minimum social safeguards. The Company is required to report, in addition to the degree of taxonomy eligibility, also on the extent of taxonomy compliance by the identified economic activities. It also has to be noted in the following that in July 2023 the EU, by its Delegated Act C (2023) 3850 amending Delegated Regulation (EU) 2021/2139, defined additional technical screening criteria for environmental objectives 1 and 2 of the EU Taxonomy Regulation, and that the EU at the same time by Delegated Act C (2023) 3851 supplementing Delegated Regulation 2020/852 for the first time defined screening criteria for environmental objectives 3 to 6. Taxonomy-eligible economic activities | To identify the taxonomy-eligible economic activities, an impact analysis was already performed last year and, building on the same, a determination of the taxonomy-eligible economic activities of RHÖN-KLINIKUM AG. On this basis we updated and supplemented the impact analysis for 2023 in a working group made up of numer- ous specialist departments and representatives from our subsidiaries and supplemented the same by environmental objectives 3 to 6. All hospital sites were included in the process of review for substantial taxonomy-eligible economic activities. | The taxonomy-eligible economic activities for 2023 identified by the analysis are set out below. As in the previous year, there were fully assigned to environmental objective 1 “climate change mitigation”. | ECONOMIC ACTIVITY Nr. 3.3 4.29 4.30 5.5 7.1 7.2 7.3 7.4 7.6 Economic activity Type of economic activity Creation of low-carbon transportation technologies Electricity generation from fossil gaseous fuels High-efficiency co-generation of heat/cool and power from fossil gaseous fuels Collection and transport of non-hazardous waste in fractions sorted at the point of collection Construction of new buildings Renovation of existing buildings Installation, maintenance and repair of energy-efficient equipment Installation, maintenance and repair of charging stations for electric vehicles in buildings (and on parking spaces belonging to buildings) Installation, maintenance and repair of technologies for renewable energies Hybrid vehicles Co-generation plants (CHPs) Co-generation plants (CHPs) Waste treatment facility Construction of new paediatric and juvenile psychiatry clinic at Marburg site incl. refurbishment of administrative building at Bad Neustadt site Installation and replacement of energy-efficient light sources; installation of air conditioning system Charging stations for electric vehicles Photovoltaic system Under the new EU Taxonomy Regulation, RHÖN-KLINIKUM AG is required to publish data on revenues (REV), capital expenditure (CapEx) and operating expenditure (OpEx) which relate to environmentally sustainable economic activities. RHÖN-KLINIKUM AG | Annual Report 2023 21 21

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Revenue KPI | As in the previous year, no revenues were identified for RHÖN-KLINIKUM AG for financial year 2023 on the basis of the criteria list which are associated with a taxonomy-eligible economic activity. | PROPORTION OF CAPEX/TOTAL CAPEX in % CCM CCA WTR CE PPC BIO Taxonomy-aligned per objective Taxonomy-eligible per objective 0 0 0 0 0 0 0 0 0 0 0 0 DNSH criteria ("Do No Significant Harm") Climate change mitigation Climate change adaptation Water and marine resources Circular economy Pollution Biodiversity and ecosystems Minimum safeguards Y/N Y/N Y/N Y/N Y/N Y/N Y/N – – – – – – – – – – – – – – – – – – – – – Proportion of Taxonomy-aligned or Taxonomy-eligible turnover – year N-1 Category (enabling activities) Category (transitional activities) % 0 0 0 0 0 E – – – – – T – – – – – RHÖN-KLINIKUM AG | Annual Report 2023 23 23

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation RHÖN-KLINIKUM AG | Annual Report 2023 25 25

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation DNSH criteria ("Do No Significant Harm") Climate change mitigation Climate change adaptation Water and marine resources Circular economy Pollution Biodiversity and ecosystems Minimum safeguards Y/N Y/N Y/N Y/N Y/N Y/N Y/N – – – – Y Y Y Y Y – – – Y Y – – Y – Y – Y – – – Y Y Y Y Proportion of Taxonomy-aligned or Taxonomy-eligible CapEx – year N-1 Category (enabling activities) Category (transitional activities) E E E E E T T % 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 10.6 33.5 0.1 44.5 RHÖN-KLINIKUM AG | Annual Report 2023 27 27

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation RHÖN-KLINIKUM AG | Annual Report 2023 29 29

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation DNSH criteria ("Do No Significant Harm") Climate change mitigation Climate change adaptation Water and marine resources Circular economy Pollution Biodiversity and ecosystems Minimum safeguards Y/N Y/N Y/N Y/N Y/N Y/N Y/N – – – Y Y Y Y – – Y – – Y Y – Y – – Y Y Y Proportion of Taxonomy-aligned or Taxonomy-eligible OpEx – year N Category (enabling activities) Category (transitional activities) E E E E E T T % 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 18.0 18.2 RHÖN-KLINIKUM AG | Annual Report 2023 31 31

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Non-financial risks | The Board of Management of RHÖN-KLINIKUM AG has imple- mented a Group-wide risk management system to detect imminent risks early on and to specifically counter them in a systematic process. At the same time, our risk management function relates not only to financial risks but also all manner of risks within the Company. We regard the risk to the life and health of our patients generally associated with a medical intervention as the greatest risk. | RHÖN-KLINIKUM AG has implemented risk reduction measures. On a net view of risks, no risks were identified that are very likely to have a serious adverse impact financial as well as non-financial aspects. | For detailed information on our risk management and our material risks, also in connection with non-financial aspects, please see section “Opportunities and Risk Report” of our Group Management Report. Our stakeholders | Our patients and their well-being are always our first priority. That is why their feedback is especially important to us. But also maintaining a continuous dialogue with our other stakeholders – first and foremost patients’ relatives, (potential) employees, the general public, the shareholders and investors, as well as the members of our network – is important to us. | FORMS OF DIALOGUE WITHIN STAKEHOLDER ENVIRONMENT Employee magazine WIR Social media Internet Internal newsletters Intranet Press releases Trade fairs Citizens’ events Conferences Open house Magazines General public (Potential) employees E-learning Partnerships with schools and universities Social media Recruiting events and drives Company events Internet Conference calls Presentations Press releases Conferences Annual General Meeting Shareholders and investors Patients and relatives Network partners Social media Internet Magazines Brochures Patient events Patient surveys Seeking personal contact through Management Project managers, etc. Head physicians RHÖN-KLINIKUM AG | Annual Report 2023 33 33

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients Cooperation with Asklepios Group further ramped up– also with digital assistance | In 2023, we steadily increased our strategic cooperation with the Asklepios Group also in the digital area, for example when reporting on medical quality and through use of a software program for ensuring and enhancing patient safety. The CIRS software we use for internal critical incident reporting allows us to report and respond to critical incidents and to create a comparison basis within the Asklepios Group. | Also in the interest of promoting patient safety, a Group-wide Clinical Risk Management Working Group was established in 2022. It is comprised of representatives from Asklepios, MediClin and RHÖN and has since held a total of seven meetings. As a result, a uniform concept for implementing clinical risk management using a software program was created in the three groups. In addition to clinical risk management, the software will also perform long-term tracking of the implementation of preventative measures and their sustainable positive impact on the safety of patients and employees. Medical strategy and objectives | We want to ensure outstanding medical care for everyone and at all times. Our goals are to continuously improve the quality of medical care, further increase patient safety and satisfaction as well as improve patient communications and patient services. We have moreover set ourselves the target of achieving an at least 90 per cent fulfilment rate for statutory quality assurance. We have achieved this self-imposed goal for 2022. And we expect to meet this target for 2023 as well. | Our medical strategy focuses on cross-sector care and digitalisation. We examine and treat our patients using the latest evidence-based therapy procedures with state-of-the-art medical technology, offer comprehensive treatment and care and in this way create the basis for sustainable treatment success. | Given the positive trend of the pandemic and low incidence numbers, the last meeting of the RHÖN Corona Taskforce was held in January 2023. Since then the pandemic has continued to be mon- itored by the RHÖN Expert Panel on Hygiene, and the RHÖN facilities are adapting the rules individually to the current development of the pandemic. The Panel last met in November 2023. In 2023, no new Group-wide pandemic rules were introduced. Further development of outpatient care | Further enhancing the already existing scope of outpatient care and cooperation of our hospitals is one of our key goals. Our aim is to avoid unnecessary inpatient hospital stays for our patients. In 2022, we established the Outpatientisation Working Group. With this goal in mind in 2023 as well, the experts participating in this Working Group developed new cross-sector concepts and strategies whilst maintaining the high quality of treatment and care provided to our patients. | The primary focus was in particular on issues arising from the hospital reform: outpatient operations, the new catalogue of opera- tions to be performed on an outpatient basis (AOP Catalogue) and the possibility of hospitals to provide day-care treatments. For this, the Working Group conducted and evaluated a survey on the status quo of outpatientisation at all RHÖN facilities. Moreover, the “Outpatientisation Strategy Day” was held in October in Bad Neustadt. Members from RHÖN’s Board of Management and the hospitals’ management bodies further developed the strategy there. | An annual conference of the medical care centres (MVZs) was held in June to promote an exchange in outpatient medicine between Asklepios, MediClin and RHÖN. | In practice we also pressed ahead with outpatientisation at the RHÖN hospitals in 2023. At the Outpatient Operation Centre (AOZ) of Bad Neustadt we established a new operating theatre enabling the implanting of cardiac pacemakers and defibrillators. At the Campus these operations in future will take place at the AOZ. The CMO, man- agement, head physician of the AOZ and project manager discuss at a regular Jour Fixe the strategic further development of AOZ Bad Neustadt. For example, they are developing ways to make patients’ stay as pleasant as possible and to ensure the quality of medical care. | Moreover, in 2023 an interdisciplinary thoraxoncological consulta- tion was introduced in Marburg. It is particularly addressed to patients with thoracic cancer diseases at a localised stage. Treating doctors from the involved medical disciplines of radio oncology, oncology and thoracic surgery can now discuss outpatient therapy schedules with these patients individually. Medical excellence | During the 2023 reporting period we took numerous additional measures to help improve medical excellence and quality for the well-being of patients. We present some select examples of these to you in the following. RHÖN-KLINIKUM AG | Annual Report 2023 35 35

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients In addition to a high standard in the quality of its medical services, a good hospital is characterised by exemplary communication with its patients and a comprehensive service offering. We meet the highest quality standards | In April 2023, the neurology clinic at Campus Bad Neustadt was able to meet the high standards for certification by the German Par- kinson Association. The clinic is one of roughly 20 Parkinson specialist clinics throughout Germany. It offers multi-modal complex therapy for patients with Parkinson's syndrome, which combines drug treatment with elements of physiotherapy, sports and occupational therapy, music therapy, speech therapy and neuropsychology. | At the University Hospital of Giessen the risk auditing company Gesellschaft für Risikoberatung (GRB) in 2023 audited the clinical areas already covered in previous year. The purpose of this was to review the work being done on areas with room for improvement identified in the preliminary audit. The auditors confirmed that clear progress had been made. Overall, we reached 94 of 100 points. | The orthopaedic unit of the University Hospital of Giessen was certified in October 2023 by the German Society for Ortho- paedy and Orthopaedic Surgery (DGOOC), the German Society for Endoprosthetics (AE) and the Professional Association of Orthopaedics and Trauma Surgery (BVOU) as an endoprosthetics centre (EPZ). This highlights the competence and quality of all the clinic’s treatment stages in the area of artificial joints. | Our Klinikum Frankfurt (Oder) in October 2023 obtained the quality seal “Certified Foot Treatment Facility DDG” from the German Diabetes Association (DDG). The clinic thus meets the high quality standards defined by the DDG for the treatment of diabetes foot syndrome. We are steadily enhancing our treatment offering | The EndoProthetikZentrum (EPZ) of the endoprosthetic unit in Bad Neustadt introduced a new concept in June 2023, the “Endo Pro® - path of quick recovery” to help patients back on their feet as early as possible following the placement of an artificial joint. The concept supports patients from their first contact with the clinic until their discharge. They thus learn in a patient school already before the operation about the medical background and find out how they can help with their recovery. | With the newly created section for neuropaediatrics at Klinikum Frankfurt (Oder), there has been a point of contact for children and youth suffering from nervous system disorders or diseases since August 2023. As part of the clinic for children’s and juvenile medicine, the new section will enable an innovative combination of outpatient and inpa- tient care. | During the reporting period, Zentralklinik Bad Berka was expanded by a geriatric rehabilitation clinic. Particularly for the elderly in our society, there is a significant care gap in the area of rehabilitation. The clinic allows those patients affected to gradually regain their indepen- dence following serious diseases or operations typically associated with old age, whilst at the same time reducing their need for nursing care. Investment was also made in a new day-care clinic. The refurbishment now allows for outpatient diagnosis of gastroenterology, outpatient infusions, chemotherapies as well as MRI diagnoses under anaesthesia. RHÖN-KLINIKUM AG | Annual Report 2023 37 37

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients | We ensure transparency in the quality of care provided by pub- lishing the legally mandatory quality reports of select specialist fields on the Internet sites of the hospitals, providing a comparison with the federal and in some cases federal state average. These publications give patients, relatives, referring doctors and health insurance funds the possibility of informing themselves extensively on the treatment quality at the hospitals of RHÖN-KLINIKUM AG. | The combined RHÖN reviews established since 2018 were also per- formed in 2023 locally at two hospitals sites. Nonetheless, we engaged with the Asklepios Group with a view to identifying areas in which we might complement each other. Clinical risk management expanded and optimised | We give top priority to the safety of our patients. During the reporting period we put into service components of a software program for an internal error reporting system, specifically the risk management, whistleblower system and audit management modules. The risk management module helps to identify relevant risks as well as establish and introduce risk mitigation measures. The whistleblower system is in response to the Whistleblower Protection Act (Hinweis- geberschutzgesetz, HinSchG). With the help of the audit manage- ment module, inspections of any kind can be planned, executed and documented. Improvement measures established from these can be plausibly monitored for implementation. For 2024, the introduction of a further module for claims management is planned. | In 2023, risk audits at all five hospital sites were carried out by the risk auditing company Gesellschaft für Risikoberatung (GRB). Our secu- rity level in clinical risk management was found to have significantly increased compared with the previous inspection. It is now at least at the same level as the average of all hospitals audited by the GRB, and in some cases at an even higher level. Patient KPIs | During the reporting period, we laid the foundations for reporting two new key performance indicators (KPIs) for 2023. The KPIs, which are based on a Group-wide standard, make it possible to compare the subgroups of the Asklepios Group. The new KPIs relate to the field of patient satisfaction in terms of the recommendation rate based on a questionnaire, as well as the subject of patient safety measured using the Critical Incident Reporting System (CIRS). As a reporting and learning system, CIRS is an essential part of clinical risk management. With CIRS all clinical employees can anonymously draw attention to errors and adverse events in clinical processes. A “learning-from- mistakes” is enabled by the system across departments and facilities. Cases of overarching relevance are passed on to all sites with specific prevention recommendations. | Patient KPIs Key performance indicator1 Critical Incident Reporting System (CIRS) Reports received Usable reports Processed CIRS reports CIRS reports with resulting measures2 Implemented measures from CIRS3 Measures from CIRS still outstanding Recommendations derived from questionnaires 1 Key performance indicators excluding Giessen site 2 Disclosure of CIRS reports with derived measures proportionate to number of usable reports in per cent 3 Disclosure of implemented measures from CIRS in proportion to number of derived measures in per cent 2023 232 62% 100% 96% 62% 41% 95% RHÖN-KLINIKUM AG | Annual Report 2023 39 39

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees Our strategic cooperation makes us a viable and attractive employer | The strategic cooperation, pooling our know-how and mutual trans- fer of knowledge between RHÖN-KLINIKUM AG and the Asklepios Group make us more resilient to the many different challenges we face as a result of energy and economic crisis, persistent staff shortages as well as healthcare policy, e.g. increasing regulation, a growing documentation workload or increasing outpatientisation. | In addition, in 2023 we continued our training cooperation scheme with the Asklepios Group at our sites in the Federal State of Hesse. The goal pursued by this intensified cooperation in the training area is to better coordinate the offerings and to offer additional joint training courses. For example, Asklepios staff obtained additional qualification to give practical training to apprentices at UKGM and staff from the UKGM attended an Asklepios teaching event for emer- gency care or wound management. | RHÖN-KLINIKUM AG is established as an independent employer brand. Working in close cooperation we have expanded our continued training and employee advisory services and now post job offers across the entire corporate group. | In the area of job applicant management, we use a uniform system at Zentralklinik Bad Berka, in some areas of RHÖN- KLINIKUM Campus Bad Neustadt and at the Klinikum Frankfurt (Oder) site. In future, we also want to offer this uniform job applicant management system at the university hospitals in Giessen and Marburg. We bring together new colleagues from Germany and abroad We look after our employees and their health | In 2023, we successfully stepped up our activities to recruit new staff from abroad, to provide them with continued and higher- qualification training and to retain them in our Company. Here we take account of cultural differences, overcoming language barriers as well enabling the smoothest possible integration. | Our overall aim as an employer is to preserve, restore or improve our employees’ health, work and performance capacity as well as their well-being and job satisfaction – depending on the specific needs. We want to help and assist our employees with various offerings, thus fulfilling our role as a responsible employer. | In Bad Neustadt we succeeded in recruiting 70 international employees, with a further 60 staff to be added next year from India, Tunisia and Western Balkan states. At the Giessen site, 100 nurses have already been recruited, with 150 additional staff members to be added in 2024, mainly from Turkey. During the reporting period, Marburg took on 17 new apprentices for the most part from Morocco, Tunisia, Iran and India. In Bad Berka, 51 employees were added from abroad, including 21 apprentices. They are from India, Tunisia, Turkey, Cameroon, Morocco and Iran. At the Frankfurt (Oder) site, up to 29 employees from Brazil will join that facility in 2024. In 2023, this site also participated in the selection process of the Global Skills Partner ship project of the Federal Ministry of Health with the Phillipines. Under the project, nursing staff were trained in their home country with course content adapted to German requirements. | Our Nursing Initiative Board is made up of representatives from all hospitals who meet regularly for an exchange of experience and ideas on the very broad subject of nursing. In the specialist bodies, specific aspects are further elaborated. Among other things, the Nursing Initiative Board looks at issues relating to the integration of foreign staff. Throughout the Group, focus issues such as the acade- misation of nursing, future-orientated workplace design and defining high-maintenance key performance indicators were formed which then reached a first implementation readiness stage in the second quarter of 2023. | Our occupational healthcare management covers the following measures: − regular visits and risk assessments − occupational integration management − operational addiction prevention − nutritional advice − de-escalation management − health reporting − psychosocial support and assistance (occupational social advice) − occupational medical care − workplace ergonomics − health conferences − occupational health promotion (various sports courses and preventative offerings) − further training in issues of relevance for health − executive training events − supervision and coaching − mediation and conflict management − resilience training RHÖN-KLINIKUM AG | Annual Report 2023 41 41

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees | We are aware that work-life balance also makes a decisive con- tribution to stable mental and physical health. We therefore see it as our responsibility to create the conditions that enable our employees to achieve a good work-life balance. We achieve this by organising working hours as flexibly as possible and introducing regulations for trust-based working hours, flexitime and part-time work. In 2023, 8,225 employees (around 45.1%) were employed part-time. We have concluded individual agreements for each location in which we take greater account of the personal priorities of the workforce. We rely on clear substitution arrangements. We also try to take personal wishes into account and set up on-call services or standby pools. | Our employees and their families also benefit from the extensive childcare offering: for example, we run our own child day-care cen- tres, cooperate with facilities locally, and provide individual childcare options for employees attending continued training courses or man- datory events. We help employees providing nursing care to relatives to cope with balancing their work with looking after their relatives. For example, UKGM has been certified as a family-friendly employer already since 2009 by Beruf und Familie GmbH of the Federal Ministry for Family Affairs. Since the end of 2021, RHÖN-KLINIKUM Campus Bad Neustadt has been part of Familienpakt Bayern (Bavarian Pact for the Family). | We have learned from the organisational challenges of the Covid-19 pandemic, and together with the Group-level works council agreed on a Group-level works council agreement for mobile working in September 2023. This allows employees to perform mobile work in specific areas for up to 50 per cent of their normal working hours. The Group-level works council agreement took effect in October 2023 and will apply initially up to and including July 2025. Putting initial, continued and higher-qualification training front and centre RHÖN-KLINIKUM AG invests in the training of new staff members and the qualification of its employees. It promotes development opportunities with numerous continued and higher-qualification training offerings addressed to all professional groups represented in the Group. That is just as true for our nursing employees as it is for our doctors and therapists. Doctors, for example, can obtain additional qualifications including specific focus areas, and can be trained as specialist doctors at all the Company’s sites. Our strategic cooperation with the Asklepios Group also opens up additional opportunities for improving the quality of continued and higher-qualification training. Expenditure on training including continued and higher-qualification training totalled roughly 5.3 million euros in 2023 – after 4.3 million euros in the previous year. At the same time, it strengthens our role as a trustworthy and valued provider of healthcare training. RHÖN-KLINIKUM AG invests in the training of new staff members and the qualification of its employees. Sitting close together in the virtual classroom Also in the 2023 reporting year, we combined the advantages of online instruction with those of in-person training. With this “blended learning” approach, we can impart both theoretical and practical knowledge to our employees. This is made possible by a learning management system (LMS) that is accessible to all employees. The already extensive offering is being continuously expanded. With the system we can also provide pre-defined mandatory training courses for specific employee groups. The instructors at the various sites coordinate the course subjects with one another. Content for the offering was created by means of an authoring tool. As planned, we have also added a new software program to the system during the reporting year. RHÖN-KLINIKUM AG | Annual Report 2023 43 43

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees HR ratios (KPIs) | HR RATIOS (KPIS) Indicator Unit 2023 2022 Staff turnover by professional group | In the 2022 Annual Report, the following KPIs were published in tabular form for the first time in addition to the previously specified key performance ratios at the Group level. The KPIs, which are based on a Group-wide standard, make it possible to compare the subgroups of the Asklepios Group. | HR RATIOS (KPIS) Indicator Unit 2023 2022 Hospital support staff Employees (incl. apprentices) headcount 18,246 18,140 Employees subject to collective agreements Employees under unlimited-term employment contracts women men Employees under limited-term employment contracts, total women men Full-time employees, total women men Part-time employees, total women men Apprenticeship places Training & development expense (initial and continued training) Professions (initial training) Women in management positions Paid sick leave Absences Medical service Medical-technical service Functional service Nursing service Medical service Nursing service Medical-technical service Functional service Operations management/ misc. service headcount 16,971 16,885 Technical service per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent quantity € m quantity per cent per cent per cent per cent per cent per cent 75.6 73.7 26.3 24.4 65.1 34.9 54.9 62.1 37.9 45.1 83.1 16.9 710 5.3 26 30.8 6.7 3.8 6.6 8.4 8.3 75.3 73.6 26.4 24.7 65.3 34.7 56.5 62.9 37.1 43.5 82.9 17.1 766 4.3 23 28.2 7.5 4.5 7.5 9.4 9.1 Administrative service Special services and training facility staff Other staff New joiners by age and gender Total, women Total, men < 20 total women men 20 – 29 women men 30 – 39 women men 40 – 49 women men 50 – 59 women men ≥ 60 women men Age structure < 20 20 – 29 30 – 39 40 – 49 50 – 59 ≥ 60 per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent per cent 17.3 11.3 14.9 11.4 20.8 23.6 10.9 12.6 11.0 56.6 67.0 33.0 11.8 14.6 6.2 43.8 44.7 42.0 23.1 20.3 28.7 12.0 11.8 12.2 6.6 6.3 7.3 2.7 2.2 3.6 2.9 21.0 24.2 19.4 21.2 11.2 17.6 11.2 14.0 15.2 26.3 28.0 22.8 25.2 14.9 57.0 64.4 35.6 14.9 18.2 9.0 43.0 44.6 40.3 22.5 20.0 27.1 11.1 10.2 12.5 6.0 5.0 7.9 2.4 2.0 3.2 3.4 21.1 23.5 19.5 22.2 10.3 EAP expense € ‘000 603.6 564.2 RHÖN-KLINIKUM AG | Annual Report 2023 45 45

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Compliance Data Protection The General Data Protection Regulation (GDPR) and the resulting revised German federal and state rules on data protection have been in force since 25 May 2018. In this context, the Board of Management of RHÖN-KLINIKUM AG adopted a data protection policy which is adapted to the rules and regulations and addresses key points of the Regulation, sets out the organisational framework for employees and thus provides the basis to ensure the best possible protection of personal data. The policy includes firstly Group-wide requirements, for example on data protection management, required rights and role concepts, on responsibilities as well as consequences in the event of breaches of requirements under data protection legislation. It more- over covers information on the operative implementation which is being adapted by the Group-affiliated facilities in the context of their own data protection concepts. Each month and on an ad hoc basis, we conduct a screening of our website using special software to ensure that our privacy policy notices there are legally compliant and accessible. To comply with the GDPR principle of data accuracy, we introduced an external soft- ware program during the reporting year. It helps us keep data stored by us, such as address details, up-to-date and to optimise the data updating process. The introduction of the whistleblowing system in 2023 was accompa- nied by a data protection impact assessment. The assessment reached by the Group data protection officer was that reports are processed through this system in compliance with data protection rules. A particular challenge has to do with the international transfer of personal data, especially whenever services from the US are used. Whenever such services are commissioned by RHÖN-KLINIKUM AG, all processors are checked to ensure they provide for an adequate level of data protection, and are also required to present relevant certifications. In addition, implementation of data protection-compliant actions is rounded off by manifold technical and organisational measures. Internal and external audits help ensure compliance with the require- ments and enable the measures established to be improved. In addi- tion, employees and executive staff are given greater awareness of the lawful management of personal data through web-based training and target group-based in-person training sessions. Data protection key performance indicator (KPI) | BREACH OF PROTECTION OF PERSONAL DATA Indicator Number of cases reported 2023 20 2022 22 Internal and external audits help ensure compliance with the requirements and enable the measures established to be improved. RHÖN-KLINIKUM AG | Annual Report 2023 47 47

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection Energy efficiency with co-generation plants | For more than 20 years, we have been generating energy using efficient co-generation plants. We also used, refurbished and expanded them in 2023. The plants deliver electrical energy and heat from burning natural gas. We also use the heat to generate the required cooling energy using absorption coolers – heat which would otherwise have to be generated by electrical energy. All that helps reduce CO2 emissions at RHÖN-KLINIKUM AG. Further reduction in climate-harmful anaesthetic gases | All anaesthetic gases are direct and potent greenhouse gases. They accelerate global warming when they enter the atmosphere through exhaust air. In 2023, we made further efforts to cut down on their use. For the most part we already previously managed to dis- continue the use of anaesthetic gas in favour of other methods such as total intravenous anaesthesia (TIVA) or regional block anaesthetics. | With co-generation plants we now cover 79 per cent of our electricity demand ourselves at the Bad Berka site, 37 per cent in Bad Neustadt, 28 per cent in Marburg and 23 per cent in Giessen. We do not operate our own co-generation plant at our Frankfurt (Oder) site. Here we purchase 100 per cent of our electricity externally and are connected to the district heating grid of the City of Frankfurt (Oder). | In 2023, work moved ahead with refurbishing the four existing co-generation plans Bad Berka. By the end of 2024, we will adapt the four existing heating boilers to the new requirements and bring the central cooling unit in line with the new operating environment in several construction stages. These measures will significantly reduce CO2 emissions and cut energy consumption by roughly 10 per cent once the project has been completed. These measures will significantly reduce CO2 emissions and cut energy consumption by roughly 10 per cent once the project has been completed. | During the reporting year 2023 we have taken further steps to harness the potential of photovoltaics (PV) at our sites. As part of a transformation concept, we have analysed the feasibility and viability of PV systems at all sites. Corresponding proposals for this are cur- rently being reviewed. Moreover, we are analysing the feasibility of power purchase agreements (PPA) with private solar farm operators. | At the Marburg site we have eliminated the use of desflurane, an anaesthetic gas which is particularly harmful for the climate, since 2022 for the most part, and at the Bad Neustadt and Giessen sites since 2023 completely. At the Bad Berka site three quarters of all desflurane vaporisers were already decommissioned. Also in Frankfurt (Oder), the use of desflurane was reduced to a minimum. At all our sites, we instead use less climate-damaging as well as cheaper gases such as sevoflurane. Likewise, we further reduced our consumption of nitrous oxide (also known as laughing gas) in 2023. Across all sites, nitrous oxide was only very rarely used, for example in special paediatric anaesthesia indications. In Marburg, anaesthetic gases are already captured with the help of an anaesthetic filter. | Moreover, in Frankfurt (Oder) 31 new electrically powered anaes- thesia apparatuses that ventilate patients without the need for driver gas have been in use since October 2023. That makes these units 13-times more energy-efficient than similar older-generation devices. We expect to achieve energy savings of around 12,000 kWh per year. Keeping buildings in good condition makes good ecological and economic sense | Ecological aspects and the potential for saving energy feature very prominently in all refurbishment measures we perform on our buildings. Also in 2023, we identified and adopted new approaches in this regard. | We continued switching over existing lighting systems used in our hospitals, outdoor installations and parking facilities to effi- cient LED technology. For all new buildings and extensions as well as moderni sation measures, we have committed ourselves to the exclusive use of LED lamps anyway. In Bad Neustadt the lion’s share of fluorescent tubes in old buildings has been replaced by LED lamps – as of September 2023 alone we replaced roughly 600 fluorescent lamps by LEDs. Also in Bad Berka and Giessen, upgrades to LED lighting were made, and in Marburg motion sensors were additionally installed. | We see further energy savings potential in refurbished heating, ventilation and air conditioning units (HVAC units). Our previous refurbishment of these units has shown that when combined with modern building automation they enable a reduction in energy RHÖN-KLINIKUM AG | Annual Report 2023 49 49

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection Sustainable mobility | In the area of mobility, we also pressed ahead with emissions- cutting measures in 2023. In Giessen two new electric cars as well as an electric van were purchased. For these, three new e-charging stations for company vehicles were installed. In Bad Neustadt, Giessen as well as Marburg, the costs for local transport of staff are covered. In Bad Berka the cost of the Deutschlandticket (D-Ticket, valid for local transport throughout Germany) has been covered for apprentices since December 2023. In Frankfurt (Oder) we offer a Job Ticket, an employer- subsidised ticket for regional transport, for example from Berlin to Frankfurt (Oder). In addition, all employees at our Bad Berka, Frankfurt (Oder), Giessen and Marburg sites qualify for our Job Bike leasing offer. In Bad Neustadt there has been a Job Bike offer since January 2024. Sustainable medical technology | We are committed to sustainability also in the area of medical technology. For example, in trauma medicine at the Bad Neustadt site we have put in place sustainable wound and bone irrigation systems (lavages). Compared with conventional single-use lavages, the ones used by us earn high marks for sustainability with the versatility of their handpieces, their phthalate-, PVC- and latex-free rinsing set materials, and their lighter-weight design thanks to their fully recy- clable aluminium housing. This can help cut waste and CO2 emissions. Measurable results | In 2023, we generated with combined heat and power units a total of 35,561 megawatt hours (MWh) (previous year: 40,296 MWh) of elec- tricity, covering roughly 32 per cent (previous year: 35 per cent) of our own demand. This is cost-efficient and in 2023 saved roughly 10,156 t in CO2 emissions as compared with conventional energy supply. Compared with the previous year, electricity consumption at RHÖN-KLINIKUM AG in 2023 saw a reduction by 3.5 per cent to 110,680 MWh (previous year: 114,723 MWh). Heat consumption decreased by about 5.0 per cent to 143,634 MWh (previous year: 151,188 MWh).1 | The lower energy requirements of our hospitals and the energy- saving measures taken have also resulted in a reduction of Scope 1 CO2 emissions. These Scope 1 emissions are produced directly on site in our own heat and electricity generation. During the reporting period, these amounted to 37,676 t of CO2 (previous year: 40,344t of CO2)2. Scope 2 emissions cover all indirect emissions from district heating and electricity deliveries. In 2023, they increased slightly to 39,520 t of CO2 (previous year: 38,333 t of CO2). Compared with the previous year, the Scope 2 figure also includes emissions from cooling media which were recorded for the first time in 2023. Reducing waste volumes through waste avoidance and recycling | Waste is unavoidable, especially in hospitals with their stringent hygiene requirements. Nevertheless, our goal is to reduce waste in the medium term. That is why RHÖN-KLINIKUM AG recognises the tremendous importance of avoiding and otherwise recycling waste as far as possible as well as ensuring proper sorting and disposal of waste. The waste officers at each of our sites monitor compliance with the regulations and train new employees and apprentices in the careful management of consumables (waste avoidance), proper segregation (recycling of raw materials) as well as the correct disposal methods for different types of waste. | We are making every effort to use all available means of recycling and to constantly find new recycling methods. We dispose of any non-recyclable waste in an environmentally sound manner to the highest disposal standards. That is why we exercise the utmost care when selecting our service providers and ensure that the disposal conditions are defined by contract. | In 2023, UKGM put special emphasis on waste management training. In Giessen, mandatory events are now held once a year for all employees with an additional waste management unit. This is especially important for new employees so that they gain heightened awareness of waste management and environmental protection as soon as they begin their work. Also in Marburg, more than 1,000 employees, and especially new team members, received further training in targeted waste management courses held in close cooperation with the occupational safety department. Increasingly, more possibilities for collecting materials in the operating theatre are being offered in cooperation with the Green Hospital Working Group. With these measures, the waste volume of both sites was already reduced significantly in 2023. | In cooperation with a medical waste specialist, single-use instru- ments are to be separately collected and recycled from 2024. Like- wise, projects are being discussed in Giessen in which cardiac catheter tips and other electrode tips containing valuable raw materials are to be collected and recycled. | We continue to offer reusable coffee cups and salad bowls in the cafeterias at our sites (except Bad Neustadt). For our patients and employees, we use resusable dishes. 1 The previous year's figure was corrected from 94,338 MWh to 151,188 MWh. 2 The previous year's figure was corrected from 45,544 tons of CO2 to 40,344 tons of CO2. RHÖN-KLINIKUM AG | Annual Report 2023 51 51

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Supplier management SUPPLIER MANAGEMENT To obtain the best quality of products at the lowest prices, we have centralised our supplier management activities for the entire Group and work together closely with the purchasing managers of our hospital sites. We will build on this proven practice also in future. Trusted, long-term partnerships with our suppliers Over the years, the business relationships with our suppliers have turned into partnerships based on mutual trust and reliability. In this way we are able to fully meet our requirements for quality, depend- ability and efficiency. This is something we notice time and again with our main suppliers in our annual supplier ratings. In addition, our top priority is for our suppliers to respect human rights and to meet the requirements of the Supply Chain Act (Lieferkettensorgfaltspflichten- gesetz, LkSG). What has proven to be a big advantage in this regard is the strategic cooperation we have been pursuing with the Asklepios Group purchasing department since October 2020. It is also respon- sible for entering into new contractual agreements. As experience has shown, this has given us an even stronger position in contract negotiations with our partners. In addition to the purely economic effects of synergies, this also pro- motes the growth in knowledge which we achieve by pooling the know-how found in the Asklepios Group. This is being done among other things through joint specialised working groups. For example, in 2023 we established two further joint groups for neuroradiology and vascular prosthetics. The cooperation has had an extremely positive effect when it comes to avoiding supply bottlenecks. For example, by working beyond the bounds of the Company and across our sites, we have been able to find solutions for what are now particularly rare goods. We reduce supply shortages by working together with at least two suppliers for each product group. Any short-term supply difficulties can usually be bridged through inventories or alternative products. Already during the purchasing phase, we thus make a decisive contribution towards the quality of our services. Inflation and regulatory challenges As before, high energy costs continue to weigh heavily on our business. We feel the effects mainly indirectly through our suppliers. Higher energy costs have a huge impact on the production costs of the items we need, as well as on transport and logistics costs. The EU Medical Device Regulation in force since May 2021 had an impact on prices also during the reporting year. The Regulation requires a new certification of medical devices. The costs associated with this are passed on by suppliers to customers, such as hospitals. Likewise, manufacturers are constantly considering the possibility of pulling low-margin products from the market instead of bearing the high costs of a certification. This is leading to shortages, pushing up costs even further. In addition to the purely economic effects of synergies, this also promotes the growth in knowledge which we achieve by pooling the know-how found in the Asklepios Group. RHÖN-KLINIKUM AG | Annual Report 2023 53 53

Group Management Report 1 | Basic characteristics of the RHÖN-KLINIKUM Group 1.1 Overview 1.2 Future of the Group 1.3 Objectives and strategies 1.4 Controlling system 1.5 Quality 1.6 Medical research and its translation into practice 1.7 Compliance 1.8 Corporate Governance 1.9 Declaration on Corporate Governance 2 | Economic report 2.1 Macroeconomic environment 2.2 Sector-specific environment 2.3 Business performance 3 | Forecast report 3.1 Strategic objectives 3.2 Economic and legal environment 3.3 Forecast 4 | Opportunities and risk report 4.1 Opportunities and Risk Management System 4.2 Risk report 4.3 Report on opportunities 5 | Reporting pursuant to section 315 (4) of the German Commercial Code (Handelsgesetzbuch, HGB) 57 57 57 58 60 60 61 61 61 63 63 63 63 64 69 69 69 70 70 70 72 75 78 RHÖN-KLINIKUM AG | Annual Report 2023 55

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group 1 | BASIC CHARACTERISTICS OF THE RHÖN-KLINIKUM GROUP 1.1 Overview Within the Group of RHÖN-KLINIKUM AG, mainly cross-sector (i.e. inpatient, semi-inpatient and outpatient) healthcare services are provided. With few exceptions, the Group has a single-tier structure. With the exception of Campus Bad Neustadt, the individual hospital companies are organised in the form of legally independent corpora- tions having their registered office at the respective facility sites and are managed as direct subsidiaries of RHÖN-KLINIKUM AG (ultimate Group parent company). The ultimate Group parent company has its registered office in Bad Neustadt a. d. Saale, Federal Republic of Germany. With eight hospitals and 5,460 beds/places at a total of five sites in four federal states, we are one of the largest hospital operators in Germany. A total of 881,775 patients (previous year: 855,333) were treated in our facilities in financial year 2023. Despite high inflation and price increases, we generated EBITDA amounting to €105.9 million (pre- vious year: €105.6 million) on revenues of €1,464.0 million (previous year: €1,446.1 million). At the balance sheet date, the Group employed 18,246 persons (31 December 2022: 18,140). Future of the Group 1.2 RHÖN-KLINIKUM AG can look back on a satisfactory financial year 2023. This is an extremely positive assessment given the highly fraught economic situation of hospitals in Germany. That is because we continue to face the tremendous challenges resulting from the rippling effects of numerous global geopolitical crises in the form of inflation and price increases as well as the increasing shortage of qualified employees in the sector. The Company continues to press ahead with its strategic objectives. The hospitals will continue to focus on their core activities, i.e. inpa- tient treatment services, and to invest in the expansion of outpatient care. Other areas of action include the optimisation of the processes which in addition to the ongoing improvement of clinical processes in particular focus on the purchasing and IT areas as well as expanding digitalisation with through modern IT systems and technologies. For the university hospital Universitätsklinikum Gießen und Marburg (UKGM), an agreement was reached at the end of lengthy, marathon negotiations between the Federal State and the managers of the Group, the universities and UKGM on its entitlement to investment funding. With the “White Paper Plus” signed at the end of February 2023, UKGM will make available nearly €850 million for investments in healthcare provision as well as research and teaching over the next ten years. Federal state funds totalling roughly €530 million coupled with own funds of roughly €320 million will enable the university hospital to implement an extensive modernisation of its medical, technical and building infrastructure. Coming on top of the over €750 million already invested in UKGM by our Company from own funds, these investments secure an important forward-looking strategy of UKGM which further strengthens its role and attractiveness as a university hospital. For RHÖN-KLINIKUM AG, acting sustainably is something non-nego- tiable. As a healthcare group, we also embrace our ecological obliga- tions in addition to our medical, social and corporate responsibilities. Our sustainability strategy is built on the three pillars: environmental, social and governance. It is being further developed on an ongoing basis. Attractiveness as employer RHÖN-KLINIKUM AG is a modern, open and diverse Company. In science and research we work in our hospitals across borders in multi-cultural teams. More than 18,200 people are employed at RHÖN-KLINIKUM AG. Roughly 1,700 people complete their training at our hospital-affiliated schools in nursing, medical, commercial and technical professions. For us, retaining our qualified employees and recruiting new staff members for our Company is hugely important. As one of the largest German healthcare service providers, we enjoy a good reputation as an attractive employer and training provider. We look after our employees, for example with offerings helping them to balance their career and family life as well as a wide range of offerings under our company health management scheme. We also offer good opportuni- ties for personal advancement and are continuously investing in initial and ongoing training and attractive work-life services for our staff. Medical and nursing excellence With RHÖN-KLINIKUM Campus Bad Neustadt, Zentralklinik Bad Berka, Klinikum Frankfurt (Oder) as well as the Giessen and Marburg University Hospitals (UKGM), RHÖN-KLINIKUM AG has five maximum- and intermediate-care hospitals throughout Germany. As academic teaching hospitals, all facilities maintain a close collaboration with research institutions. The strong interdisciplinary cooperation and individual therapies for our patients based on state-of-the-art diagnostics enable a holistic provision of medical, nursing and therapeutic care to patients. RHÖN-KLINIKUM AG and its locations enjoy a high standing in the medical community. Our hospitals are certified to provide high quality treatment. Many of them hold multiple certifications. RHÖN-KLINIKUM AG | Annual Report 2023 57

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group On the one hand, our hospitals in future will continue to focus on their core activities, i.e. on inpatient treatment services, with the goal of being able to provide our patients with cutting-edge medical care at all sites and anytime. Above and beyond that we will continue to invest in the expansion of outpatient care so that we can offer patients alternatives to an inpatient hospital stay meeting the high quality of medical care standards without having to sacrifice the standard of care provided in a hospital. In addition to ongoing efforts to improve our clinical processes, our goal is to optimise the processes and further press ahead with prod- uct standardisation. At the same time, we have defined standards for processes and medical devices in all our facilities which are adopted across all sites. Improvements in margins that can be achieved thanks to size advantages in purchasing as well as positive economies of scale require a sound business development and stable internal financing so that in future also we can continue making investments in our healthcare facilities. We continue to pursue our objective of taking on new challenges and, meeting them through appropriate investments. In addition to medical advances, we have move ahead even faster with digitalisa- tion. State-of-the-art systems and technologies are indispensable in all areas. Clinical information systems are increasingly being net- worked with medical equipment. The prerequisite for this to have a suitable IT infrastructure that not only meets the technical standards but above all satisfies the highest safety standards as well. In future we will continue to use funds from the Hospital Future Fund (KHZF) to make further improvements to IT security, particularly given the steadily growing risks posed to critical infrastructure in the hospital area as well. The conceptual and constructional modernisation of our sites contin- ues to be a further significant goal. In Germany, we have a very good healthcare system with highly qualified and committed employees. To make sure this stays that way in future, this heavily regulated sys- tem must be funded in line with the principle of dual financing. That means that the operating costs are borne by the healthcare funds and the investment costs of the hospitals by the federal states regardless of their ownership (public or private) and their care level or category. It is therefore vital for the federal states to step up to the plate and once again better meet their statutory responsibility to assume the investment costs and to ensure the future viability of hospitals in Germany. For Universitätsklinikum Gießen und Marburg, an agree- ment was reached between the State Government of Hesse and the managers of our Group, the universities and the university hospital on the latter’s entitlement to investment funding. In February 2023, the “White Paper Plus” was signed under which nearly €850 m will be invested in healthcare provision as well as research and teaching over the next ten years. We are firmly convinced that Universitätsklinikum Gießen und Marburg can look ahead to very good prospects in the long term. Our extensive Group-wide investments will provide a positive impetus for medical care to patients. As a healthcare group, we are also embracing our future ecological obligations in addition to our medical, social and corporate responsi- bilities. A part of our sustainable activities, we intend to reach climate neutrality by financial year 2040. To achieve this, we have created a transformation concept showing the scope for energy conservation and utilisation potential and have developed a catalogue of measures serving as a roadmap for our environmental strategy. Already now we invest in sustainable technologies, continuously optimise our processes and consider waste avoidance and water consumption reduction as essential when it comes to protecting the environment without compromising on the safety and comfort of the care we provide to our patients. Our objectives continue to be ambitious and will present RHÖN-KLINIKUM AG and our employees with a wide range of chal- lenges. RHÖN-KLINIKUM AG is a modern, open and diverse Company. Every day, people from over seventy nations work together in a team and do outstanding work. Here, we pay considerable attention to retaining and recruiting qualified staff, particularly also given the general shortage of qualified staff in the medical and nursing fields. With the shortage of nursing staff seen nationally, our goal is to recruit qualified professionals from abroad. That is why we have stepped up our recruiting measures and international contacts to recruit nurs- ing staff in over twenty countries and will do everything we can to enable their good integration. We continue to offer our employees good opportunities for personal advancement and are continuously investing in initial and ongoing training as well as in attractive work- life offerings for our staff. Not a few hospitals will have to close down due to the huge cost pres- sures and as a result of the planned hospital reform. We continue to face the tremendous challenges resulting from the rippling effects of numerous global crises and the associated huge cost burdens in the areas of energy, medical supplies or services. Many different structural changes are needed to safeguard the efficiency of the healthcare system in Germany. RHÖN-KLINIKUM AG | Annual Report 2023 59

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group 1.6 Medical research and its translation into practice Thanks to the direct tie-in to university maximum care and the direct access to university research findings made possible with the Giessen and Marburg university hospitals, the healthcare facilities of RHÖN-KLINIKUM AG can translate state-of-the-art research findings quickly and precisely into medical care and effectively deliver it to the regions. Our excellent healthcare is based on this continuous transfer of knowledge from research into daily clinical practice. Our hospitals collaborate in national and international research associations and projects and benefit from the close networking as well as strategic exchange within the Asklepios Group. 1.7 Compliance The compliance standards at RHÖN-KLINIKUM AG promote a legally compliant conduct of our employees. This is sustained and supported throughout our Group – both internally within our Company and in the relationship with our external stakeholders. Our sustainable corporate activity is built on trust and integrity. The trust between clinical staff and patients is the basis of our day- to-day work. We understand this in the light of the principle that “we treat all people in the same way we also would like to be treated our- selves”. This principle applies without exception to all our employees. Our compliance management system provides the framework for legally compliant behaviour, fair dealings and responsible corporate governance. It is continuously being enhanced and promoted. In our Group-wide principles of conduct, requirements setting out the relationship with our patients, customers, suppliers, shareholders and the general public as well as the conduct of employees amongst one another are described. Further information can be found in the separate Non-Financial Report (NFB) for the Group pursuant to sections 315 b, 315 c in conjunction with sections 289 b to 289 e HGB in the Annual Report published on our website. 1.8 Corporate Governance Subscribed capital The subscribed capital of RHÖN-KLINIKUM AG stated in the consoli- dated financial statements is completely made up of 66,962,470 ordi- nary voting bearer shares (non-par shares) each having a nominal share in the registered share capital of €2.50. Restrictions on voting rights or the transfer of shares – even if these may result from agreements of shareholders – do not exist or are not known to us. None of our shares is issued with special rights that confer on its holder special powers of control. Employees who hold shares exercise their voting right freely. Shareholders may exercise their voting rights themselves at the Annual General Meeting or through proxies appointed for this purpose. Based on the threshold events notified to us, the following picture pursuant to section 33 f. of the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG) in terms of shareholder structure emerges as at the relevant key date of 31 December 2023: Person subject to notification requirement Published on Held directly % Attributed % Date that interest exceeds/falls below the threshold Interest exceeding/ falling below threshold of Voting rights held % Notification pursuant to section 33 f. WpHG Attribution pursuant to WpHG/ additional information: Dr Bernard große Broermann/ Eugen Münch; AMR Holding GmbH 23 July 2020/ 24 July 2020 0.0005 93.37 93.38 22 July 2020 > 75% Attributed (section 34 WpHG): AMR Holding GmbH Consolidated financial statements, communication with shareholders and analysts The consolidated financial statements are drawn up in accordance with the provisions of International Financial Reporting Standards (IFRS) applicable within the European Union and applying section 315 e of the HGB, and audited in accordance with both national and international auditing standards. When issuing auditor mandates, due care is taken to ensure the requisite independence of the auditors appointed. The audit mandate for the annual and half-year financial statements of the Group as well as for the Group's ultimate parent company is issued by the chairman of the Audit Committee after due examination pursuant to the resolutions adopted at the Annual General Meeting. RHÖN-KLINIKUM AG | Annual Report 2023 61

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group | Economic report Other contracts containing a change-of-control clause The White Paper Plus (Zukunftspapier Plus) signed at the end of February 2023 between the Federal State of Hesse, RHÖN KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universitätsklinikum Gießen und Marburg GmbH (UKGM), as well as their universities with their faculties of medicine, relating to the granting of investment funds for UKGM provides, as of 1 January 2023, for a re-transfer of shares to the Federal State of Hesse under certain circumstances in the event of a change of control. A change of control exists if 50.0% of the shares in RHÖN-KLINIKUM AG or more than 50.0% of the shares in Asklepios Kliniken GmbH & Co. KGaA or its personally liable share- holder is acquired by another natural or legal person. Various contracts relating to financial instruments exist in which the lenders may demand immediate re-payment in the event of a change of control. In this regard a change of control is defined as the takeover of more than 50.0% of the interests in RHÖN-KLINIKUM AG. For the former anchor shareholders B. Braun Melsungen AG/Asklepios Kliniken GmbH & Co. KGaA/Mr. Münch (HCM SE) and Ms. Münch, exceptions did and do exist in the promissory note loan agreement from financial year 2018 and the registered bond from financial year 2019. According to the contract documentation, no change of control exists if one or more of the former anchor shareholders acquire(s) more than 50.0%, but no more than 70.1% maximum (promissory note loan agreement 2018) and 70.3% maximum (registered bond 2019), respectively, of the voting shares in RHÖN-KLINIKUM AG within the group of anchor shareholders. Declaration on Corporate Governance 1.9 The Declaration on Corporate Governance, in addition to the Declara- tion of Compliance of the Board of Management and the Supervisory Board pursuant to section 161 of the AktG, also contains information on corporate governance practices, the work approach of the Board of Management and the Supervisory Board as well as the committees established by them, reporting on equal participation of men and women in management positions and the diversity concept. For further details please visit our website www.rhoen-klinikum-ag.com where the Declaration on Corporate Governance is made accessible to the public under the section “Corporate Governance”. 2 | ECONOMIC REPORT Macroeconomic environment 2.1 In 2023, the German economy stagnated as it struggled with high, albeit declining inflation. The was attributable above all to massive losses in purchasing power resulting from the crisis in energy prices that weakened private consumption. The downbeat trend on the global economy and with it weak foreign demand hampered Ger- many’s export-driven economy, already under pressure from signifi- cantly higher energy prices. Coming on top of this were the subduing economic effects resulting from geopolitical tensions and crises. The mood in the German economy deteriorated in December 2023. After reaching 90.1 points in January 2023, climbing to 91.5 points in May 2023 and declining to 87.2 points in November 2023, the ifo business climate index further declined to 86.4 points in December 2023. Price-adjusted gross domestic product was 0.3% lower in 2023 compared with the previous year. The effects of the week economy could also be seen on the labour market. Unemployment and underemployment saw a significant increase on average over 2023, with the number of unemployed persons increasing by 191,000 to 2.609 million compared with the previous year. The jobless rate stood at 5.7% as an annual average for 2023. In December of the previous year, the rate was 5.3%. 2.2 Sector-specific environment Like the economy as a whole, hospitals have been hugely impacted by price increases as a result of significant uncertainties in connection with the geopolitical risks since 2022. In addition to high inflation which has now subsided again, high collective wage increases cou- pled with a lack of refinancing as well as increasing outpatientisation with insufficient financial and structural framework conditions are responsible for the massive deterioration in the financial situation of hospitals seen over the past years. This has confronted hospital operators with a tremendous challenge. On 10 July 2023, the Federal Government and the States reached agreement on the key points of a hospital reform. On 22 September 2023, the Federal Ministry of Health tabled a first working draft for an act that is to contain provisions on improving the quality of care delivery in hospitals and reforming remuneration structures. The working draft is currently in further consultations between the Federal Government and the Federal States. The hospital reform provides for reforming the system of purely volume-based DRG remuneration and introducing a merely indirectly volume-dependent component in the form of remuneration for maintaining the availability of capac- ities. Under this scheme, the existing case flat rates (DRGs) are to be lowered. The level of financing capacity availability is to be linked to service groups which are assigned to the individual hospitals by the Federal States and which require the hospitals to meet uniformly defined quality criteria. The hospital reform now offers the opportu- nity to tackle fundamental challenges like the chronic underfunding of hospitals in Germany. However, the Federal Government’s current RHÖN-KLINIKUM AG | Annual Report 2023 63

GROUP MANAGEMENT REPORT | Economic report Approved beds/places Change 31 Dec. 2023 31 Dec. 2022 absolute in % 2.3.3 Results of operations For computational reasons rounding differences of ± one unit (€, %, etc.) may occur in the tables below. If data are provided below on individual companies, these are values before consolidation. Consolidated performance figures developed as shown below: –0.1 in € million January to December 2023 2022 in % Change Income Revenues Other income Total Expenditure 1,464.0 1,446.1 272.4 220,1 1,736.4 1,666.2 Medical care centres Specialist practices Materials and consumables used Employee benefits expense Other expenditure 488.5 974.4 167.3 446.6 949.8 164.2 61.75 Result of impairment on financial assets 0.3 0.0 1,630.5 1,560.6 17.9 52.3 70.2 41.9 24.6 3.1 0.3 69.9 1.2 23.8 4.2 9.4 2.6 1.9 n.a. 4.5 Inpatient capacities Acute hospitals Rehabilitation hospitals and other inpatient facilities Semi-inpatient and day-clinical capacities Total 4,629 4,634 612 602 5,241 5,236 219 209 5,460 5,445 –5 10 5 10 15 1.7 0.1 4.8 0.3 As at 31 December 2023, we operate nine medical care centres with a total of 60.75 specialist practices: As at 31 December 2022 Opened/acquired MVZ Bad Berka MVZ Bad Neustadt a. d. Saale MVZ Frankfurt (Oder) Disposals MVZ Bad Berka MVZ Marburg As at 31 December 2023 9 – – – – – 9 0.25 0.50 1.00 –2.00 –0.75 60.75 Total EBITDA Depreciation/amortisation and impairment EBIT Finance result EBT Income taxes Consolidated profit 105.9 105.6 0.3 0.3 65.5 40.4 7.3 47.7 7.5 40.2 69.5 36.1 –2.5 33.6 6.7 26.9 –4.0 4.3 9.8 14.1 0.8 13.3 –5.8 11.9 > 100.0 42.0 11.9 49.4 Patient numbers at our hospitals and medical care centres developed as follows: January to December 2023 2022 absolute in % Change Inpatient and semi-inpatient treatments at our Acute hospitals 187,600 189,803 –2,203 –1.2 Rehabilitation hospitals and other facilities Outpatient attendances at our 5,301 5.056 245 192,901 194,859 –1,958 Acute hospitals 476,091 452,491 23,600 Medical care centres 212,783 207,983 4,800 Total 688,874 660,474 28,400 881,775 855,333 26,442 4.8 –1.0 5.2 2.3 4.3 3.1 Despite the discontinued reimbursements by the German legisla- tor in connection with COVID-19 legislation, revenues rose to by €17.9 million or 1.2% to reach €1,464.0 million above all as a result of the increase in the state base rates. Whereas inpatient and semi- inpatient case numbers were down by 1,958 cases or 1.0% as a conse- quence of the strike at the Giessen and Marburg university hospitals early in the year, we recorded a rise in outpatients by 28,400 cases or 4.3%. In line with the trend in inpatient and semi-inpatient patients, our cost weights likewise saw a slight decline to around 179,000 cost weights compared with the previous year. During the same period of the previous year, revenues still included €77.6 million in income in connection with COVID-19 legislation, This mainly related to relief amounts for beds kept available as well as care surcharges paid to hospitals for extraordinary charges as a result of the Corona virus. The rise in other income by €52.3 million or 23.8% is mainly attrib- utable to higher income from ancillary and incidental activities RHÖN-KLINIKUM AG | Annual Report 2023 65

GROUP MANAGEMENT REPORT | Economic report Cash and cash equivalents increased in financial year 2023 by €128.7 million (previous year: decrease by €49.0 million). In this context, a positive operating cash flow was achieved in the amount of €109.0 million (previous year: €60.3 million). In addition to the increase in operating cash flow by €48.7 million over the previ- ous year, we report a €146.1 million increase in cash generated from investment activity as well as a €17.1 million increase in cash used in financing activity, in each case compared with the previous year. For further explanations, we refer to the Notes to the Consolidated Financial Statements of RHÖN-KLINIKUM AG. The finance management department of RHÖN-KLINIKUM Group is essentially centrally organised and encompasses the functions of rais- ing capital, capital investment, Group-internal liquidity management as well as settlement. The processes implemented give due regard to the fundamental principles of checks performed by a second person, segregation of functions as well as transparency. We have established the finance management department as a service provider within our business model. Our finance management has to deal with the competing goals of securing liquidity, minimising risk, and ensuring profitability and flexibility. In this regard, top priority is given to securing liquidity with the objective of realising terms at matching maturities and in line with the Company’s planning and project horizon. To secure the Compa- ny’s liquidity, internal cash flows are available. Cash is invested on conservative terms. As at the balance sheet date, we have cash investments available in the short term as well as available credit lines together amounting to roughly €440.8 million. 2.3.5 Investments Aggregate investments of €62.6 million (previous year: €56.0 million) in financial year 2023 are shown in the following table: 2023 2022 in € million 109.0 60.3 40.9 –105.2 Current investments Use of grants Use of own funds 29.8 – 29.8 32.6 0.2 32.8 Total 62.4 0.2 62.6 Takeovers Total –21.2 128.7 77.3 206.0 –4.1 –49.0 126.3 77.3 During financial year 2023, we invested a total of €62.6 million (previous year: €56.0 million) in intangible assets as well as in property, plant and At 72.3%, the equity capital ratio is still at a high level. As at 31 December 2023, equity stands at €1,280.2 million (previous year: €1,251.4 million). The increase in equity capital compared with the reporting date of 31 December 2022 by €28.8 million results from consolidated profit of financial year 2023 (€40.2 million) and from gains from the revaluation of defined benefit pension plans (€0.0 million), on the one hand, and dividend payments to share- holders of RHÖN-KLINIKUM AG and non-controlling interests (€10.9 million) as well as losses from the change in the fair value of equity investments through other comprehensive income (FVOCI) (€0.5 million), on the other. 146.2% (previous year: 139.1%) of non-current assets is nominally cov- ered by equity and non-current liabilities at fully matching maturities. As at 31 December 2023, we report net liquidity of €192.8 million (31 December 2022: €138.1 million). Net liquidity is calculated as follows: in € million Current cash Current fixed term deposits Cash, fixed term deposits Current financial liabilities Non-current financial liabilities Liabilities under leases Financial liabilities 31 Dec. 2023 31 Dec. 2022 206.0 136.8 342.8 1.0 141.8 7.2 150.0 77.3 219.0 296.3 8.0 141.7 8.5 158.2 Net liquidity 192.8 138.1 The origin and appropriation of our liquidity are shown in the fol- lowing overview: in € million January to December Cash generated from (+) /cash used in (–) operating activities Cash generated from (+)/cash used in (–) investing activities Cash generated from (+) /cash used in (–) financing activities Change in cash and cash equivalents Cash and cash equivalents at 1 January Cash and cash equivalents as at 31 December RHÖN-KLINIKUM AG | Annual Report 2023 67

GROUP MANAGEMENT REPORT | Forecast report 3 | FORECAST REPORT 3.1 Strategic objectives Given the rapid pace of developments on the healthcare market it is our goal to continue setting new milestones in future as well and together with Asklepios to gain an even stronger position on the market and will continue benefiting from the strategic cooperation and standardisation of processes and products. Also in future we will develop and promote path breaking concepts of healthcare delivery to ensure we can continue providing excellent medical care. In addition to advances in medicine, we will press ahead even further with digitalisation and drive the change on the healthcare delivery landscape by promoting specialisation whilst expanding outpatient medicine through comprehensive and targeted investments. At the same time, our hospitals will continue to focus on their core activities, i.e. on inpatient treatment services, with the goal of being able to provide our patients with cutting-edge medical care at all sites and anytime. Besides retaining and recruiting qualified medical and nursing staff, it is also very important for us to meet our future environmental com- mitments. As part of our sustainable activities, we intend to reach climate neutrality by financial year 2040. RHÖN-KLINIKUM AG’s objective is to pursue new paths to uphold the standard of offering patients the best medical care. In this way we can better respond to the changes and increasing requirements as compared with the market as a whole thanks to the merger with Asklepios and our large sites with highly specialised centres. With a view to continuing to improve patient care along the lines of our campus approach to ensure cross-sector and future-viable health- care provision in Germany, we are also looking at further developing innovative remuneration and care models. For further information, please also refer to section 1.3 “Objectives and strategies” in this Group Management Report. Economic and legal environment 3.2 At the turn of the year, leading economists and economic institutes once again lowered their forecasts for economic output in Germany for 2024. Most pundits expect a small decline, with growth in gross domestic product (GDP) being barely noticeable or even non-exis- tent. Currently early indicators are still not signalling a quick recovery in the economy. But according to the Federal Ministry for Economic Affairs and Climate Action, the major negative factors weighing on the German economy are likely to diminish in the course of 2024 as inflation declines, real wages rise and the global economy gradually recovers with a predominantly domestic economic recovery setting in. The forecast of leading economists for the trend in German GDP fluctuate between –0.5% and +1.3%. In its forecast from October 2023 the German government was still expecting GDP of +1.3% for 2024. The forecast for the jobless rate for 2024 will be around 5.9%, according to the Ifo Institute. The previous year’s figure was 5.7%. With the health reform plans currently being presented by the Federal Ministry of Health, the hospital landscape might be headed for far-reaching changes. The current draft provides among other things for reorganising the system of purely volume-based DRG remu- neration and additionally introducing a largely volume-independent remuneration component for the services of somatic hospitals for keeping capacities available. The level of remuneration for capacity availability is to be linked to service groups which are assigned to the individual hospitals by the Federal States and which require hospitals to meet uniformly defined quality criteria. The hospital reform in prin- ciple offers the opportunity to tackle fundamental challenges like the chronic underfunding of hospitals in Germany. However, the Federal Government’s current reform proposal has still failed to address the key questions of implementation and funding. In particular, it would come as no big surprise if the introduction of a third remuneration component for capacity availability alongside the existing DRG-based remuneration and a separate budget for financing nursing payroll costs were to simply lead to more red tape and greater bureaucratic expenses for hospitals. Nonetheless, we believe the position of our hospitals makes us well prepared for the impending reform. According to the Hospital Rating Report, the potential workforce will decline significantly in the coming years as the baby boomers gradually head for retirement and low-birth generations enter the job market. This will further exacerbate the shortage of qualified staff in the medical and nursing area. RHÖN-KLINIKUM AG | Annual Report 2023 69

GROUP MANAGEMENT REPORT | Opportunities and risk report The basis for our risk management system is the Group risk guide- line containing both the risk strategy and objectives, the definition of the term ‘risk’ and the principles of risk management, as well as describing the requirements for the risk management process uniformly binding on the Group as a whole including the related duties and responsibilities. The actual risk management process is documented in a risk management software program. Thanks to an open risk culture, regular training and feedback sessions, we ensure acceptance of risk management within the Company. The Internal Auditing department is entrusted by the Board of Management with the process-related review of matters as required in specific cases. In this connection, it also monitors the operability and correct applica- tion of the corresponding requirements in sub-divisions or companies of RHÖN-KLINIKUM AG. Definition By risks we understand events and potential developments within and outside RHÖN-KLINIKUM AG that might adversely impact the achieve- ment of the Company’s stated objectives, future performance of tasks as well as the quality and reputation of RHÖN-KLINIKUM AG and its subsid- iaries. By analogy to the definition of risk, we understand opportunities as events and potential developments that may have a positive impact. Risk management process We understand risk management as an ongoing process that is divided into the phases of: − risk identification, − risk analysis and evaluation, − risk control and management, − risk communication, − risk monitoring. These processes are to ensure that potential risks are made manage- able and opportunities are identified. All risks meeting the definitions of the Group risk guideline are to be reported. At the same time, our risk management function relates not only to financial risks but also all manner of risks within the Company. We regard the risk to the life and health of our patients potentially resulting from a medical intervention as the greatest risk. With us, identifying risks and recognising opportunities are integrated into our standard business procedures, since it is only when we are aware of risks and opportunities that we can manage and control them. Risk identification encompasses the systematic and structured documentation of all relevant risks in the Company, with risk classes always being assessed in terms of their strategic and operative impacts as well as in view of the risks of reporting and potential compliance risks. Given constantly changing circumstances and requirements, risk identification is an ongoing task, and is performed on a decentralised basis in accordance with responsibilities defined in the individual Company divisions. Any relevant risks identified are categorised and recorded within the risk management system in a centrally predefined risk catalogue. Risks identified are systematically analysed and evaluated in the con- text of the individual risk bearing capacity by those entrusted with such tasks. In the risk analysis, risks identified are aggregated and then analysed for the purpose of early detection to determine whether individual risks of secondary importance when viewed in isolation may lead to a higher or existential risk by reason of their combined or cumulative effects over time. We classify developments with an expected risk value of 10% or more of EBITDA as existential risks when set against with the individual risk bearing capacity. The risk bearing capacity of RHÖN-KLINIKUM AG and its subsidiaries is determined from the comparison between risk cover amount and risk exposure. The expected risk value (product of damage amount and probability of occurrence) is the expected damage extent giving due regard to the probability of occurrence and refers to the target values (EBITDA) for the respective financial year. Not all risks are to be weighted equally. To ensure efficient risk man- agement, we perform a systematic assessment of the risks identified. Within the context of risk evaluation, the probability of occurrence and potential monetary damage amount of the risk are determined, also giving due regard to already existing and planned measures. Using a risk matrix, probability of occurrence and damage amount are classified to the four levels: “low”, “moderate”, “high” and “very high”. Probability of occurrence is assigned to the following categories depending on their amounts: − Low: > 0% to < 30% − Moderate: 30% to < 60% − High: 60% to < 80% − Very high: 80% to < 100% The potential damage amount refers to the target values for the respective financial year and is always calculated as a negative impact on EBITDA. Classification to the impact categories takes place inde- pendent of EBITDA: − Low: up to 5% of EBITDA − Moderate: up to 10% of EBITDA − High: up to 25% of EBITDA − Very high: from 25% of EBITDA RHÖN-KLINIKUM AG | Annual Report 2023 71

GROUP MANAGEMENT REPORT | Opportunities and risk report have to be reduced throughout Germany and outpatient capacities ramped up. In January of this year, as a first step towards ensuring the future viability cross-sector equal remuneration, hybrid DRGs for select services were introduced and the Catalogue of Outpatient Operations and Procedures Substituting for Inpatient Care in Hospitals (also referred to as the AOP Catalogue) was broadened to include further services. We are gearing our efforts towards ensuring that we can achieve the continuous economic growth in service volumes needed in our core business with our already implemented campus approach, also in future. With the health reform plans currently being presented by the Fed- eral Ministry of Health, the hospital landscape might be headed for far-reaching changes. The current draft provides among other things for reorganising the system of purely volume-based DRG remuner- ation and additionally introducing a largely volume-independent remuneration component for the services of somatic hospitals for keeping capacities available. The level of remuneration for capacity availability is to be linked to service groups which are assigned to the individual hospitals by the Federal States and which require hospitals to meet uniformly defined quality criteria. The hospital reform in prin- ciple offers the opportunity to tackle fundamental challenges like the chronic underfunding of hospitals in Germany. However, the Federal Government’s current reform proposal has still failed to address the key questions of implementation and funding. In particular, it would come as no big surprise if the introduction of a third remuneration component for capacity availability alongside the existing DRG-based remuneration and a separate budget for financing nursing payroll costs were to simply lead to more red tape and greater bureaucratic expenses for hospitals. Nonetheless, we believe the position of our hospitals makes us well prepared for the impending reform. As far as possible, the above developments have already been taken into account in our targets. Looking to the future, we will counter them through suitable activities and measures. Further regulatory and industry risks relating to us are classified as low. The new pro- visions of the legislator may lead to further risks for the hospitals of RHÖN-KLINIKUM AG. Since we pursue a comprehensive risk management approach, the identification and any assessment of non-financial risks may also arise from the analysis of financially assessed risks. In this context, compliance risks of our Group are particularly important when it comes to assessing sector-specific risks. These include the mandatory observance of statutory provisions (e.g. data protection regulations). Climate-related aspects are also becoming increasingly important and may have a negative impact on the results of operations. Currently, no financial impacts have been identified in these areas. The regulatory and industry risks relate both to the strategic and the operative risks as well as the compliance risks of our Group. Risks to service volumes In Germany, hospitals approved under state hospital planning enjoy de facto state regulated protection in their respective catchment area. Traditional market and revenue risks exist only where site closures are ordered or a hospital’s quality is assessed by referring physicians or by patients as significantly worse than that of neighbouring hospitals. In the latter case, that results in large numbers of patients switching to other hospitals. Increasing shifts in service volumes from the inpatient to the outpatient area are also making themselves felt. In addition, regulatory requirements such as defined staffing floors as well as minimum volumes for performing select procedures can result in a hospital no longer being allowed to provide certain services in future. Service volume fluctuations in our facilities, increasing outpatientisa- tion, regulatory requirements and possible quality-related markdowns may lead to revenue losses and, together with increases in personnel, material and energy costs, to diminished earnings. Through regular period-based and inter-operation comparisons with regard to service volumes, revenues and earnings as well as selected business ratios and other key performance indicators (KPIs), it is possible for us to identify adverse developments early. Where it is appropriate and nec- essary, we can take corrective action and manage a reasonably low risk potential in terms of the operative risks as well as reporting risks. To ensure our efficiency also in future and to further improve profit- ability, RHÖN-KLINIKUM AG is working together with the subsidiaries of the Group of Asklepios Kliniken GmbH & Co. KGaA on various opti- misation measures. The risks to service volumes relate in particular to operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Operating risks We see some of our most pressing tasks for our Company in the following areas of action: strengthening nursing and medical care, ensuring that hospitals concentrate on their core activities, expanding outpatient care structures and our digital structures and offerings, further optimising our processes as well as pooling specialised know- how e.g. at the (in some cases newly established) service companies providing in-house services. We are tackling these areas with the involvement of all our employees, helped by our collaboration with the companies of the Asklepios facilities. RHÖN-KLINIKUM AG | Annual Report 2023 73

GROUP MANAGEMENT REPORT | Opportunities and risk report Procurement risks In the area of materials management, RHÖN-KLINIKUM AG is working together closely with Asklepios Großhandelsgesellschaft mbH under a cooperation agreement aimed at strengthening care security at the sites with adequate conditions. For materials procurement in the areas of medical facilities, equipment as well as medical supplies and energy supply, we rely on external providers. These business ties can give rise to risks that are triggered, for example, by supply and quality problems. Already during the pan- demic, supply shortages and product unavailability had increased and were then exacerbated even further by geopolitical crises (Ukraine, Israel). The procurement problems and price increases associated with that have now become a reality in day-to-day business operations and are taken into account in planning and the multiyear forecast. Thanks to the cooperation agreement with Asklepios and measures already taken, we continue to assess the risk in the purchasing area as low overall. Procurement risks relate in particular to operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Financial risks RHÖN-KLINIKUM AG is characterised by a high and sound capital base, a sustainable internal financing strength and a strong liquidity position in the triple-digit million euro range. Our three-pronged financing strategy consists of a syndicated, undrawn line of credit, a promissory note and a long-term registered bond. We rate financing and liquidity risks as currently low. Since we operate exclusively in Germany, we are not subject to any currency risks. Except for 24,000 treasury shares and a commercial paper with a term of one month, no securities are held within the Group of RHÖN-KLINIKUM AG. For security reasons, other cash invest- ments must be spread over the three large deposit security systems (savings banks sector (Sparkassensektor), cooperative banking sector (genossenschaftlicher Sektor), and banking association (Bankenver- band)). Counterparty banks may only be credit institutions subject to German deposit protection. The maximum cash investment exposure to a counterparty banks is limited by the amount of the deposition protection limit. Any remaining credit rating and rate risks are closely monitored. The finance risks relate in particular to operative but also strategic risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Overall assessment RHÖN-KLINIKUM AG has implemented risk reduction measures. In the context of the risk evaluation for financial year 2023 on a status quo view of risks, no risks were identified that are or will be very likely to have a serious adverse impact on the Group. Neither were any risks posing a threat to the Company’s existence reported. The principles of the statutorily prescribed system of early identification of risks jeopardising the Company’s existence were continued in the reporting year as in the previous years. As an overall assessment based on our analysis of the risk position within the Group and at its subsidiaries for financial year 2023, we have concluded that there are no risks that could endanger the existence of the subsidiaries or the Group of RHÖN-KLINIKUM AG, and do not see any matters having an adverse effect on corporate development. The risks at the individual companies as well as at the Group as a whole continue to be rated as low. 4.3 Report on opportunities To take advantage of opportunities, it is sometimes necessary to deliberately accept potential risks. Taking just one example: any medical intervention will expose patients to a risk, but at the same time also holds out the prospect or opportunity of recovery and/or cure. Our management of opportunities thus covers the totality of all measures promoting the systematic and transparent handling of opportunities. The process and communication paths involved are similar to risk management. Our 50-year anniversary as a company in 2023 has once again driven home the realisation of the outstanding role we have always played as a highly innovative company in the healthcare sector. Time and again in our 50-year history we have set new milestones in patient care and medicine in Germany, and that is something we will con- tinue to do in future as well. This includes our campus approach for comprehensive, cross-sector healthcare provision which is one step ahead of the impending healthcare reform, or the flow principle by which hospital organisation was re-invented already decades ago, to name just a few examples. Entrepreneurial freedom, but also taking a dynamic approach, embracing change and striving for future viability have always been the hallmarks of our corporate success. That is why we have always thrived with our hospitals especially in sometimes difficult conditions and challenging times. RHÖN-KLINIKUM AG | Annual Report 2023 75

GROUP MANAGEMENT REPORT | Opportunities and risk report way with the strongest and most forward-looking trends in healthcare through digital networking and integration of all those involved in the treatment process: community-based practitioners, rehab facilities and other providers further down the chain of care delivery. In this context, digital solutions funded by the German Hospital Future Act (KHZG) help to decide on the right form of healthcare provision and to thus take advantage of the opportunities offered by outpatientisation. For that reason, it will be even more important for decision-making processes ensuring the best possible care to be made already before patients are admitted to the hospital based on a digital integration of emergency dispatch centres and emergency services. Last year, further outpatient offerings were added at all our sites. For example, at the Outpatient Operation Centre (AOZ) of Bad Neustadt a. d. Saale we established a new operating theatre enabling the implanting of cardiac pacemakers and defibrillators. At Klinikum Frankfurt (Oder) there is a new innovative point of contact for children and youth suffering from nervous system disorders or diseases that combines outpatient and inpatient care. The hospital Zentralklinik Bad Berka modernised and expanded its outpatient diagnostic services, including in the area of laboratory services. Since October 2023, the University Hospital of Giessen has been cooperat- ing with the neurology department of Lahn-Dill-Kliniken in Wetzlar which in special consultations transfers outpatients to Giessen. In Marburg an interdisciplinary thoracic oncological consultation was introduced and the outpatients’ department expanded as a coordi- nation centre for post-COVID and post-vac patients. The post-COVID outpatients’ department has outstanding clinical and experimental expertise and is one of the few points of contact in Germany and throughout Europe for patients with post-COVID and post-vac. For the establishment of a post-COVID coordination centre, the Federal State of Hesse provides funding in this year alone of more than €145,000 to improve the care provided to patients. The expansion of the post- COVID outpatients’ department into a network coordinator will make it possible among other things to refer patients with a particular con- dition to specialised general practitioners (GPs) or other specialists. The aim of the coordination centre is to manage expertise, data and resources digitally and to create the basis for a virtual post-COVID institution. Overall, the project is slated for three years. In addition to the expansion of outpatient care and the advance in digitalisation, the conceptual and constructional modernisation of our sites continues to be a major issue. Our extensive investments at almost all sites of the Group will result in positive impacts on medical care for patients. For the Giessen and Marburg universities, the “White Paper Agreement Plus” with the Federal State of Hesse was signed at the end of February 2023. Over the next ten years, funds totalling almost €850 million will be allocated to investments in healthcare delivery, research and teaching and will enable the university hospital to implement an extensive modernisation of its medical, technical and building infrastructure. The new “White Paper Plus” and the collec- tive wage agreement for job security and relief provides the university hospital with big opportunities for its successful future development with the aim of achieving noticeable relief for the different work areas. Responsibility, sustainability, integrity, trust and loyalty are values to which our Company and its employees have always felt committed right from the start. As a healthcare group, we also embrace our eco- logical obligations in addition to our medical, social and corporate responsibilities and make good use of the advantages of a sustainable orientation. It is about being more efficient, raising the Company’s image, but also creating better opportunities when it comes to recruiting junior staff. Overall, we see ourselves very well positioned thanks to the partner- ship with Asklepios. Also in future, we will continue to be amongst the major hospital operators in Germany operating as an efficient, homogenous Group with a consistent orientation and focus on cutting-edge medicine geared towards maximum care, as well as the further strengthening of treatment excellence and patient care through our focus on digitalisation and network medical care. To this end we avail ourselves of all opportunities presented to us and counteract the potential risks with a practised and functioning risk management approach. RHÖN-KLINIKUM AG | Annual Report 2023 77

Consolidated financial statements Consolidated balance sheet Consolidated income statement Consolidated statement of comprehensive income Statement of changes in equity Statement of cash flows Notes Contents of the consolidated financial statements General information Accounting policies Critical estimates and assessments in accounting and valuation Company acquisitions Notes to the consolidated income statement Notes to the consolidated balance sheet Statement of cash flows Shareholdings Other disclosures Corporate bodies of RHÖN-KLINIKUM AG Responsibility statement Independent auditor’s report 80 82 83 84 85 86 86 88 88 102 105 106 111 132 134 135 146 149 150 RHÖN-KLINIKUM AG | Annual Report 2023 79

CONSOLIDATED FINANCIAL STATEMENTS | Consolidated balance sheet Notes 31 Dec. 2023 31 Dec. 2022 6.12 6.13 6.14 6.15 6.17 6.3 6.13 6.14 6.16 6.19 6.15 6.17 6.18 167,406 574,168 510,542 –76 167,406 574,168 482,304 –76 1,252,040 1,223,802 28,186 27,631 1,280,226 1,251,433 141,776 141,675 547 5,000 7,213 289 519 0 20,234 0 154,825 162,428 961 173 66,835 8,846 34,691 11,514 212,453 335,473 7,966 0 69,986 11,205 33,964 11,576 156,386 291,083 1,770,524 1,704,944 EQUITY AND LIABILITIES in € ’000 Shareholders' equity Issued share capital Capital reserve Other reserves Treasury shares Equity attributable to shareholders of RHÖN-KLINIKUM AG Non-controlling interests in equity Non-current liabilities Financial liabilities Provisions for post-employment benefits Other provisions Other financial liabilities Deferred tax liabilities Current liabilities Financial liabilities Provisions for post-employment benefits Trade payables Current income tax liabilities Other provisions Other financial liabilities Other liabilities RHÖN-KLINIKUM AG | Annual Report 2023 81 81

CONSOLIDATED FINANCIAL STATEMENTS | Consolidated statement of comprehensive income Consolidated statement of comprehensive income 1 JANUARY TO 31 DECEMBER 2023 € '000 Consolidated profit of which non-controlling interests shareholders of RHÖN-KLINIKUM AG Notes 2023 2022 40,167 26,940 1,455 38,712 1,796 25,144 Changes in fair value through other comprehensive income (FVOCI) Income taxes Other comprehensive income (changes in fair value through other comprehensive income) not subsequently reclassified to income statement Revaluation of defined benefit pension plans Income taxes Other comprehensive income (revaluation of pension plans) not subsequently reclassified to income statement 6.5 6.3 6.14 6.3 Other comprehensive income1 of which non-controlling interests shareholders of RHÖN-KLINIKUM AG Total comprehensive income of which non-controlling interests shareholders of RHÖN-KLINIKUM AG 1 Sum of value changes recognised directly at equity. –590 93 –497 75 –12 63 –434 – –434 303 –47 256 98 –15 83 339 – 339 39,733 27,279 1,455 38,278 1,796 25,483 RHÖN-KLINIKUM AG | Annual Report 2023 83

CONSOLIDATED FINANCIAL STATEMENTS | Statement of cash flows Notes 2023 2022 5.9 5.5 6.6 6.7 6.8 et seq. 6.16 6.15/6.17 et seq. 6.14 et seq. 5.10 6.1 et seq. 6.5/6.8 6.5 4 6.13 9.3 6.12 6.12 6.11 47.7 –7.3 65.6 106.0 –0.9 –0.9 –51.8 –0.2 69.0 1.0 –9.7 –3.5 109.0 –62.8 10.1 82.7 – –0.2 0.6 10.5 40.9 –7.0 –3.3 –10.0 –0.9 –21.2 128.7 77.3 206.0 33.6 2.5 69.6 105.7 –0.2 –15.7 –57.7 2.6 38.5 1.0 –9.3 –4.6 60.3 –58.2 0.1 –53.0 4.6 –0.3 0.4 1.2 –105.2 – –3.5 – –0.6 –4.1 –49.0 126.3 77.3 85 Statement of cash flows in € million Earnings before taxes Finance result (net) Depreciation/amortisation and impairment and gains/losses on disposal of assets Change in net current assets Change in inventories Change in trade receivables Change in other financial assets and other assets Change in trade payables Change in other net liabilities/other non-cash transactions Change in provisions Income taxes paid Interest paid Cash generated from operating activities Investments in property, plant and equipment and in intangible assets Government grants received to finance investments in property, plant and equipment and in intangible assets Change in investments in fixed term deposits Investments in financial assets Acquisition of subsidiaries, net of cash acquired Sale proceeds from disposal of assets Interest received Cash generated from/cash used in investing activities Repayment of financial liabilities Principal payments for leases Dividend payments to shareholders of RHÖN-KLINIKUM AG Payments to non-controlling interests in equity Cash used in financing activities Change in cash and cash equivalents Cash and cash equivalents as at 1 January Cash and cash equivalents as at 31 December RHÖN-KLINIKUM AG | Annual Report 2023

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Contents 106 106 107 107 107 108 108 108 108 109 109 110 110 111 111 114 116 117 117 117 117 117 118 119 120 120 121 121 122 123 6.14 Provisions for post-employment benefits 125 6.15 Other provisions 126 6.16 Trade payables 126 6.17 Other financial liabilities 127 6.18 Other liabilities 127 6.19 Current income tax liabilities 6.20 Derivative financial instruments 127 6.21 Additional disclosures regarding financial instruments 128 6.21.1 Carrying amounts, recognised figures and fair values according to measurement categories 128 6.21.2 Net gains or losses by measurement category 131 6.21.3 Financial liabilities (maturity analysis) 131 7 | Statement of cash flows 8 | Shareholdings 8.1 Companies included in the consolidated annual report 8.2 Other companies according to section 313 (2) No. 2 et seq. HGB 9 | Other disclosures 9.1 Average annual number of employees 9.2 Other financial obligations 9.3 Leases within the Group 9.4 Related parties 9.5 Total payments of Supervisory Board, the Obligations of lessees Investment property 9.3.1 9.3.2 Board of Management and the Advisory Board 9.6 Declaration of Compliance with the German Corporate Governance Code 9.7 Disclosure of the fees recognised as expenses (including reimbursement of outlays and excluding VAT) for the statutory auditors 9.8 Events after the reporting date 10 | Corporate bodies of RHÖN-KLINIKUM AG 132 134 134 135 135 135 135 136 136 137 137 141 145 145 145 146 87 Notes to the consolidated income statement 5.1 Revenues 5.2 Other income 5.3 Materials and consumables used 5.4 Employee benefits expense 5.5 Depreciation and impairment 5.6 Other expenses 5.7 Result from impairment on financial assets 5.8 Research costs 5.9 Finance result – net 5.10 Income taxes 5.11 Non-controlling interests in profit 5.12 Earnings per share 6.5 6.6 Inventories 6.7 Trade receivables 6.8 Other financial assets (current) 6.9 Other assets (current) 6.10 Current income tax assets 6.11 Cash and cash equivalents 6.12 Equity 6.13 Financial liabilities 5 | 6 | Notes to the consolidated balance sheet 6.1 Goodwill and other intangible assets 6.2 Property, plant and equipment 6.3 Deferred tax assets and deferred tax liabilities 6.4 Financial investments accounted for using the equity method 6.4.1 Investments accounted for using the equity method 6.4.2 Joint ventures Other financial assets (non-current) RHÖN-KLINIKUM AG | Annual Report 2023

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies The Standards and Interpretations adopted by the European Union are explained below: Amendments to IFRS 17: “Insurance Contracts” The amendments to IFRS 17 “Insurance Contracts” were adopted into European law on 19 November 2021. They provide that for contracts with participation features, as are common in Germany and a number of other EU countries, entities are given the option of being exempted from applying IFRS 17.22. IFRS 17.22 provides that in the subsequent measurement only those contracts concluded no more than one year apart may be measured together. When utilising the exemption, entities may now measure contracts in the subsequent measure- ment together, regardless of the time interval between conclusion of the contracts, and prior to applying the imparity principle may net profitable and loss-making contracts concluded at very different times. The amendments are to be applied to financial years begin- ning on or after 1 January 2023 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IFRS 17: “Insurance Contracts” – initial application of IAS 17 and IFRS – Comparative Information With the amendments to Standard IFRS 17 “Insurance Contracts”, first- time adopters of this Standard can present financial assets during the comparative period as if the classification and measurement rules in IFRS 9 had been applied to such financial assets (classification overlay). The amendments adopted into European law on 8 September 2022 are to be applied to financial years beginning on or after 1 Janu- ary 2023 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IAS 1: “Presentation of Financial Statements” – Scope of Accounting Policies in an IFRS appendix The amendments to IAS 1 “Presentation of Financial Statements” clarify that in future disclosures are to be made only for material and no longer for significant accounting policies. In this regard, accounting policies relating to immaterial transactions or events are in turn to be regarded as immaterial and thus not subject to disclosure. Here, immateriality is to be assessed not only quantitatively but also qualitatively. Accounting policies relating to material transactions or events may be material but do not necessarily have to be. The Standard contains information and explanations on when disclosures on accounting policies are to be regarded as material. The basic prin- ciples to be considered for determining when an accounting policy is deemed material were also included in the IFRS Practice Statement 2 “Making Materiality Judgements” and explained in the form of a deci- sion tree. The amendments, which were adopted into European law on 2 March 2022, are to be applied to financial years commencing on or after 1 January 2023 and have no material impact on the net assets, financial position and results of operations of RHÖN-KLINIKUM AG. Amendments to IAS 8: “Accounting Policies” – Definition of an Accounting Estimate The amendments to IAS 8 “Accounting Policies, Changes in Account- ing Estimates and Errors” clarify the distinction between accounting policies and accounting estimates and redefine the term “account- ing estimates”. Under the new definition, “accounting estimates” are monetary amounts in financial statements that are subject to measurement uncertainty. The term “accounting estimate” thus represents a value which, in the case of existing measurement uncertainties, is determined using measurement techniques and input factors to achieve the objective of the accounting policy to be applied. The amendments, which were adopted into European law on 2 March 2022, are to be applied to financial years commencing on or after 1 January 2023 and have no material impact on the net assets, financial position and results of operations of RHÖN-KLINIKUM AG. Amendments to IAS 12: “Income Taxes” – Recognition Prohibition for Deferred Tax on Initial Recognition of an Asset or Liability The amendments to IAS 12 “Income Taxes” qualify the initial recog- nition exception (IRE). Up to now, it prohibited an entity from recog- nising deferred tax on initial recognition of an asset or liability in a transaction which is not a business combination and affects neither accounting nor taxable profit. Under the revised IRE, the question of the recognition or non-recognition of deferred tax assets or liabilities is broadened to include the question of whether or not the trans- action at the same time gives rise to equal deductible and taxable temporary differences. If this question is answered in the affirmative, and if the further conditions are satisfied, recognition of deferred tax assets or liabilities occurs. Otherwise, no recognition of deferred tax assets or liabilities occurs despite further conditions being satisfied. In practice, particularly in the case of leases in the context of recognition of a right of use and a lease liability, this now means that, possibly in derogation to the existing accounting practice, both deferred tax assets and deferred tax liabilities are to be recognised – provided that equal deductible and taxable temporary differences arise. Non- recognition of deferred tax is no longer allowed. The general netting provisions of IAS 12.74 are to be observed. The amendments, which were adopted into European law on 11 August 2022, are to be applied to financial years commencing on or after 1 January 2023 and have no material impact on the net assets, financial position and results of operations of RHÖN-KLINIKUM AG. Amendments to IAS 12: “Income Taxes” – International Tax Reform: Expedients for the Accounting of Deferred Taxes The amendments to IAS 12 “Income Taxes” include a temporary, man- datory exemption to the accounting obligation for deferred taxes arising from the global minimum tax, and specific disclosures in the notes to the financial statements for entities concerned to enable the users of the financial statements to understand the entity’s exposure RHÖN-KLINIKUM AG | Annual Report 2023 89

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies Amendments to IAS 1: “Presentation of Financial Statements” – Classification of Liabilities as Current or Non-current, Non- current Liabilities with Covenants The amendments to IAS 1 adopted in January 2020 relate to a limited adjustment in the assessment criteria for the classification of debt as current or non-current. It is clarified that the classification of debt as current depends on the entity’s rights on the relevant reporting date to defer settlement of the debt by at least twelve months after the end of the reporting period: if such rights exist, the debt is classified as non-current. In this regard, the right to defer the settlement of the debt must have substance. If the entity has to fulfil certain conditions to exercise such a right, these must be fulfilled on the relevant report- ing date; otherwise the debt is classified as current. In this context it is not relevant to the classification of a debt whether the management intends or expects the debt to actually be settled within 12 months of the reporting date. The only decisive factor for the classification is the right existing on the relevant reporting date to defer settlement of the debt by at least 12 months. This also applies if the liability is settled within the adjusting events period. The amendments (after the date of initial application of the amend- ments was meanwhile postponed from 1 January 2022 to 1 January 2023 by amendments from July 2020) were supplemented by an additional amendment to IAS 1 published in October 2022. The new amendment concerns the classification of debts that are subject to covenants. The IASB clarifies that covenants to be met before or on the reporting date may have an effect on the classification as current or non-current. In contrast, covenants that are only to be met after the reporting date have no influence on the classification. Instead of being taken into account in the classification, such covenants are to be disclosed in the notes. This is intended to enable users of financial statements to assess the extent to which non-current liabilities could become repayable within 12 months. The amendments, which were incorporated into European law on 19 December 2023, are now to be applied to reporting periods beginning on or after 1 January 2024. Early (joint) application of the amendments is permitted. The Group currently believes that no material impact on the consol- idated financial statements will arise. By the end of the date of preparation of the consolidated financial statements, the other Standards and Interpretations were not yet adopted by the European Union. For that reason, no detailed expla- nation of these Standards and Interpretations is given. c) Estimates Preparing consolidated financial statements in accordance with IFRS requires assumptions and estimates to be made. Moreover, the appli- cation of Group-wide accounting policies means that management has to exercise reasonable judgment. Areas that call for a greater degree of judgment to be exercised or that are characterised by a higher degree of complexity, or areas for which assumptions and estimates are of decisive importance for the consolidated financial statements, are set out and explained. The preparation of the con- solidated financial statements was based on historical cost, qualified by the financial assets and financial liabilities recognised at fair value through profit or loss as well as the equity investments measured directly in equity. Reference is moreover made to Note 3 "Critical esti- mates and assessments in accounting and valuation” in these Notes. d) Publication The consolidated financial statements adopted by the Board of Management on the signing date will be adopted, approved and released for publication by the Supervisory Board on 27 March 2024. 2.2 Consolidation The annual financial statements of the companies included in the consolidated annual report have been prepared in accordance with uniform accounting and valuation principles in relation to the same date as the consolidated financial statements. Subsidiaries 2.3 As a general rule, subsidiaries are all entities (including structured entities) which a group has the possibility of controlling pursuant to IFRS 10. When assessing whether control exist, it is examined whether the parent has power over the subsidiary, obtains positive or negative variable returns and from it can influence the amount of such returns through exercising its power. Subsidiaries are included in the consolidated financial statements (full consolidation) from the date that the Group obtains control and are deconsolidated when the control ends. Acquired subsidiaries are accounted for using the purchase method. The cost of the acquisition is measured as the fair value, at the transac- tion date, of assets rendered, equity instruments issued, and liabilities incurred or acquired. They also contain the fair values of all recognised assets and liabilities resulting from a contingent consideration agree- ment. Upon their first-time consolidation, assets, liabilities and contin- gent liabilities identifiable within the scope of a business combination are recognised separately at their fair values at the acquisition date. For each company acquisition the Group decides on a case-by-case basis whether the non-controlling interests in the acquired company are recognised at fair value or based on the proportionate share in the net assets of the acquired company. Costs relating to the acquisition are expensed as incurred. RHÖN-KLINIKUM AG | Annual Report 2023 91

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies Sale of subsidiaries and associated companies 2.3.3 If the Group loses either control or material influence over a company, the remaining interest is re-measured at fair value and the resulting difference recognised as profit or loss. Fair value is the fair value cal- culated upon the initial recognition of an associate, joint venture or financial asset. Moreover, all amounts stated in other income are recognised with reference to such company in the same way as would be required if the related assets and liabilities had been sold by the parent company directly. That means that a profit or loss previously recognised under other income is reclassified to the income state- ment. If it cannot be reclassified to the income statement, it remains in equity (e.g. actuarial profits or losses from pensions). 2.3.4 Segment reporting According to IFRS 8 “Operating Segments”, segment information on operating segments is to be presented in accordance with the inter- nal reporting to the chief operating decision maker (management approach). An operating segment is a company component − which carries out business activities from which revenue is earned and for which expenses may be incurred. For us these include all revenues relating to services provided directly and indirectly for patients, as well as all expenses necessary for providing services, − whose operating result is regularly reviewed by the company’s chief decision maker to make decisions about resources to be allocated to this segment and assess its earnings strength, and − for which separate financial information is available. The chief decision making body in our Group is the Board of Management. It is in this body that the strategic decisions are made for the Group and to this body that the key ratios of the hospitals, which represent our operating segments, are regularly reported. Monthly reporting to the Board of Management includes the hospi- tals. Group management costs are fully distributed to the operative segments. The monthly target-to-actual and actual-to-actual com- parison in the report to the Board of Management, by aggregating the operative segments into one reporting segment, serve to control the targets published in the Company forecast. Given our understanding of an integrated healthcare services offering, we do not make any distinction in control by whether the services as defined in German social insurance legislation are attributed to the inpatient or the outpatient sector, or to the rehab or nursing sector. All expenses and income which are directly or indirectly related to patients are included under the operating segments. The operating segments are aggregated to one reporting segment since they exhibit similar economic characteristics. As a result of the same structural framework conditions, the operating segments in the Group with the healthcare services provided are characterised by a similar risk and rewards profile whose economic environment is largely regulated by legislation. The politically desired state inter- ference is felt both on the income side and with expenses. It is thus possible for the operating segments to achieve similar EBITDA mar- gins. We thus continue to have only one operating segment subject to reporting. We generate all revenues for all our areas of activity in Germany. We generate most of our revenues in the inpatient, outpatient, rehab and nursing area with the statutory health insurance funds, the state pension insurance agency, the statutory occupational insurance agencies and the other public healthcare institutions. Only a small share of revenues is generated with private health insurance funds or self-payers. Regarding the breakdown of revenues by business areas and federal states, we refer to section 5 of the Notes. 2.4 Goodwill and other intangible assets 2.4.1 Goodwill Goodwill is the excess of the cost of the company acquisition over the Group's interest in the fair value of the net assets of the acquired company at the acquisition date. Goodwill arising on acquisitions is allocated to intangible assets. Goodwill is subjected at least to an annual impairment test and measured at its historical cost less any impairment losses. A review is also performed when there are events or circumstances indicating that the value might be impaired. Impair- ment losses are not reversed. Profits and losses arising on the sale of a company include the carrying amount of the goodwill allocated to the company sold. RHÖN-KLINIKUM AG | Annual Report 2023 93

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies Government grants are recognised on a systematic basis either in profit or loss, and during periods in which the Company applies cor- responding expenditures which the government grants are intended to cover as expenses. Financial assets 2.8 Financial assets in principle comprise receivables, other financial assets, equity instruments, derivative financial instruments with pos- itive fair values, and cash. 2.7 Impairment of property, plant and equip- ment and intangible assets (excl. goodwill) The Group assesses on every balance sheet date whether there are any indications that an asset might be impaired. If such indications exist or if an annual impairment test has to be performed in relation to an asset, the Group estimates the recoverable amount. If it is not possible for independent inflows to be allocated to the individual asset, the Group estimates the recoverable amount for the cash gen- erating unit to which the asset belongs. The recoverable amount is the higher of the fair value of the asset less costs to sell it and its value in use. If the carrying amount of an asset exceeds its recoverable amount, the asset is considered to be impaired and is written down to its recoverable amount. In order to calculate the value-in-use, the estimated future cash flows are discounted to their present value using a discount rate before taxes which reflects the current market expectation with regard to the interest effect and the specific risks of the asset. Impairments are shown in the income statement under the item “Depreciation/amortisation and impairment”. On every balance sheet date, a test is performed to establish whether there are any indications that an impairment recognised in previ- ous reporting periods no longer exists or might have diminished. If such an indication exists, the recoverable amount is estimated. An impairment previously recognised has to be reversed if there has been a change in the estimates used for determining the recover- able amount since the last impairment was recognised. If this is the case, the carrying amount of the asset has to be increased to the recoverable amount of the asset. However, this must not exceed the carrying amount which would have resulted after the recognition of depreciation/amortisation if no impairment had been recognised in previous years. Any such reversal of a prior impairment has to be recognised immediately in the profit or loss for the period. After a prior impairment has been reversed, the amount of depreciation/ amortisation in future reporting periods has to be adjusted in order to systematically distribute the revised carrying amount of the asset, less any residual value, over the remaining useful life of the asset. These financial assets are principally divided into the following cate- gories as defined in IFRS 9: − Measured at fair value through profit or loss − Measured at fair value directly in equity (fair value through other comprehensive income, without recycling) − Measured at amortised cost − Measured at fair value directly in equity (fair value through other comprehensive income, with recycling) All purchases and sales of financial assets are recognised at the settle- ment date, i.e. the date when the purchase or the sale is transacted. Derivative financial instruments are recognised on the trading date. Initial recognition of financial assets not measured as at fair value through profit or loss takes place at fair value plus transaction costs. Assets measured at fair value directly in equity (fair value through other comprehensive income, without recycling) are measured after initial recognition at their fair values. Financial assets in the category of ‘amortised cost’ are carried at amortised cost using the effective interest method. Financial assets are derecognised if the rights to payments from the investment expire or have been transferred and the Group has substantially transferred all the risks and rewards of ownership of the financial asset. Investments in equity instruments (equity interests) are carried in accordance with IFRS 9 at RHÖN-KLINIKUM AG as fair value through other comprehensive income (without recycling). These are strategic investments and the Group considers this classification to be more meaningful. Related gains and losses from the sale are not reclassified in the income statement. If no active market exists for financial assets or if these assets are not listed, the fair values are calculated using suitable measurement methods. These may include references to recent transactions between independent business partners, the use of current market prices of other assets that are substantially similar to the asset under consideration, discounted cash flow methods, as well as option price models which make use as far as possible of market data and as little as possible of individual company data. RHÖN-KLINIKUM AG | Annual Report 2023 95

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies 2.10 Inventories Inventories within the Group of RHÖN-KLINIKUM AG are materials and supplies. These are measured at the lower of cost (including transaction costs) and net realisable value. Cost of inventories is determined by the weighted-average method. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs to sell. 2.11 Trade receivables Trade receivables are initially recognised at the transaction price plus any transaction costs and subsequently measured at amortised cost less impairments. The Group generates its revenue for the most part from the statutory health insurance funds. The material part of accounts receivable likewise is likewise due from statutory health insurance funds. For calculating expected credit losses, we have used the country default risk for the Federal Republic of Germany as a basis for this category of receivables. In the case of the other receivables, the Group uses aged debtor lists and past experience as the basis for collectively estimating the percentage of expected credit losses as at the balance sheet date in relation to the period of time overdue. Macroeconomic risks are included with a time lag in the assessment through the country default risk of the Federal Republic of Germany or through the individual receivables defaults. Receivables are derecognised within the Group of RHÖN-KLINIKUM AG after expiry of the legally prescribed limitation periods or after conclusion of unsuc- cessful insolvency proceedings. In addition, the Group recognises specific valuation allowances if, as a result of particular circumstances, it is not likely that trade receivables will be recovered. Cash and cash equivalents 2.12 Cash and cash equivalents comprise cash on hand, demand depos- its, and other short-term, highly liquid financial assets with original maturities of up to three months. Utilised bank overdrafts are shown on the balance sheet as liabilities to banks under the item “Current financial liabilities”. 2.13 Equity Ordinary shares are classified as equity. Costs that are directly attrib- utable to the issuance of new shares are recognised in equity (net of tax) as a deduction from the issuance proceeds. If a company belonging to the Group acquires treasury shares of RHÖN-KLINIKUM AG, the value of the consideration paid including directly attributable additional costs (net of tax) is deducted from the equity capital attributable to shareholders of the company until the shares are either redeemed, re-issued or re-sold. If such shares are subsequently re-issued or re-sold, the consideration received, net of directly attributable additional transaction costs and related income tax, is recognised in the equity attributable to the shareholders of RHÖN-KLINIKUM AG. 2.14 Financial liabilities Financial liabilities in principle comprise financial debt (including the negative fair values of derivative financial instruments), trade payables as well as other financial liabilities. Loan liabilities are classified as current liabilities unless the Group has the unconditional right to postpone settlement of the liability to at least twelve months from the balance sheet date. Financial liabilities as well as financial debt are initially recognised at fair value (less transaction costs). In subsequent periods they are mea- sured at amortised cost; any difference between the disbursement amount (after deduction of transaction costs) and the repayment amount is recognised over the term of the loan in the income state- ment in the finance result using the effective interest method. Derivative financial instruments, if any exist, are measured at fair value. For current financial liabilities this means that they are recognised at their repayment or settlement amount. 2.15 Current and deferred taxes The tax expense of the period is made up of current and deferred taxes. Taxes are recognised in the income statement unless they relate to items which were directly recognised in equity or in other income. In this case, taxes are likewise recognised in equity or other income. Deferred tax is recognised using the liability method for all temporary differences between the tax carrying amounts of assets and liabilities and the respective IFRS consolidated carrying amounts. If, however, in a transaction which is not a business combination, deferred tax arises from the initial recognition of an asset or liability which at the time of the transaction affects neither accounting nor taxable profit or loss, no deferred tax is recognised. Deferred taxes are measured RHÖN-KLINIKUM AG | Annual Report 2023 97

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies The present plans are multi-employer plans (IAS 19.8) since the par- ticipating companies share both the risk of the capital investment and the actuarial risk. In principle, the VBL/BVK benefit plan is to be classified as a defined benefit plan (IAS 19.38), but the information needed for an objectively correct representation of the Group’s share of the future payment is not available due to the existing PAYGO financing regime. Because of such PAYGO financing approach in which the levy rate is calculated for a certain coverage layer on the basis of the aggregate insurance portfolio and not on the basis of the individual risk of insurees, the benefit plan pursuant to IAS 19.34 is to be recognised as a defined contribution plan. Since no agreements within the meaning of IAS 19.37 exist, there is no recognition of a corresponding asset or liability. The recognition of any liability item in the balance sheet is subordinate to priority-ranking guarantee obligations of public-law entities. In the event of a VBL participation being terminated, the legal con- sequences arising therefrom are defined in section 23 of the VBL Rules. Termination of a VBL participation also triggers the end of the mandatory insurance schemes. Since the VBL also continues to settle the pension claims and entitlements arising up to the end of the participation, the withdrawing party, as compensation, is required to pay an equivalent value which does not include those components financed under the funded scheme. This equivalent value comprises the full funding of existing entitlements and coverage of adminis- trative expenses as well as future benefit claims. The supplementary pension insurance scheme ZKV also stipulates a similar provision. Since in the case of withdrawal from PAYGO financing the risks of the other participants of the system also have to be compensated pro rata, a plausible actuarial calculation can be made only by the pension fund itself. The current contributions to the VBL/BVK are reflected in the employee benefits item as pension expenses or post-employment benefits for the respective years. Membership in VBL/BVK exists only due to the acquisition of hos- pitals from public ownership. Universitätsklinikum Gießen und Marburg GmbH is a member of the VBL, and RHÖN-Kreisklinik Bad Neustadt GmbH is a member of the BVK. In addition to the levy, the VBL also levies reform imposts from the participating employers with compulsory insurees in the separately organised and managed settlement class Abrechnungsverband West. In financial year 2023, the reform impost amounted to 0.00% (previous year: 0.13%) of the insured remunerations. In the settlement class Abrechnungsverband West, the VBL finances its benefits through a PAYGO approach taking the form of a modi- fied defined period-based funded approach (Abschnittsdeckungs- verfahren). The current defined period covers 2016 to 2023. The levy rate is assessed in such a way that the contribution to be paid for the duration of the defined period together with the other income expected and the available assets suffices to settle the expenditures during the defined period and the period of six months thereafter. Since 1 January 2023, the levy rate has been 7.30% (previous year: 7.86%) of the remuneration subject to supplementary pension pay- ments, of which employers pay a share of 5.49% (previous year: 6.45%) and employees a share of 1.81% (previous year: 1.81%). The contribu- tion rate in the BVK, depending on the year of the employee’s entry, is between 4.80% (previous year: 4.8%) and 7.75% (previous year: 7.75%). Given insufficient information, it is not possible to make any statement on the level of participation in the pension schemes based on the contributions paid by the Group of RHÖN-KLINIKUM AG compared with the aggregate payments to the VBL and other public service pension schemes (BVK). 2.16.2 Termination benefits Termination benefits are provided if an employee is made redundant before the normal retirement date or accepts voluntary redundancy in return for severance compensation. The Group recognises sever- ance compensation payments if it is committed to terminating the employment of current employees subject to a detailed formal plan which cannot be rescinded or is committed to paying severance com- pensation if employees accept voluntary redundancy. Termination benefits which fall due more than twelve months after the balance sheet date are discounted to their present value. 2.16.3 Management profit sharing and employee profit sharing Management profit sharing and employee profit sharing are rec- ognised as liabilities using a measurement method based on the consolidated result or the results of consolidated subsidiaries. For target agreements, a liability is recognised on the basis of the target achievement rates. The Group recognises a liability in cases where a contractual obligation exists or an obligation arises from a past practice. RHÖN-KLINIKUM AG | Annual Report 2023 99

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies 2.22.2 Credit risk The Group provides the predominant portion of its services to mem- bers of the statutory social insurance scheme, and the remainder to persons who have taken out private health insurance and pay medical invoices themselves. There are no significant concentrations with respect to individual payers. The cost of hospital services is nor- mally settled by payers within the legally prescribed period. With regard to the default risks in financial year 2023, please refer to our comments in the sections “Trade receivables” and “Other financial assets”. The maximum risk of default is equal to the aggregate amount of the financial assets (less impairments) recognised on the balance sheet. Counterparty risks from entering into financial transactions are minimised by adherence to rules and limits. 2.22.3 Liquidity risk Careful liquidity management includes holding a sufficient reserve of cash, having the possibility of obtaining finance for an ade- quate amount under agreed credit lines, and being able to raise liquidity from market issuances. Given the dynamic nature of the market environment in which the Group operates, the objective of RHÖN-KLINIKUM AG is to maintain the necessary flexibility in finance matters by having sufficient credit lines available and access to the capital markets at all times. A minimum strategic liquidity of cash and free, immediately available credit lines is held in order to ensure the Group’s ability to act at all times. To monitor liquidity risk, a liquidity report is prepared daily and a treasury report monthly. Short- to medium- term liquidity planning calculations are also carried out. 2.22.4 Interest rate risk Interest rate risk results from uncertainty about future developments in the level of interest rates and affects all interest-bearing items as well as interest derivatives. RHÖN-KLINIKUM AG is therefore always exposed to interest rate risks. As at the balance sheet date, 62.1% (previous year: 26.0%) of cash at banks was invested at a variable interest rate or callable daily, and 37.9% (previous year: 74.0%) at a fixed interest rate with a maximum residual term of up to five months (previous year: eleven months). For leases with a term of twelve months maximum as of 1 January 2019 as well as leases relating to low-value assets, no right of use and no lease liability will be applied in the balance sheet and the lease payments will continue to be recognised as an expense as thus with a negative effect on EBITDA in the income statement. 2.20 Costs of borrowing If borrowing takes place, the costs of borrowing are deducted from the corresponding items and are distributed using the effective- interest method. Moreover, the interest is then recognised as current expense. Costs of borrowing incurred in connection with the acquisition/construction of qualifying assets are capitalised during the entire production process until commissioning. Other costs of borrowing are recognised as an expense. 2.21 Dividend payments Shareholders’ claims to dividend payments are recognised as a liability in the period in which the corresponding resolution is adopted. 2.22 Financial risk management 2.22.1 Financial risk factors The assets, liabilities and planned transactions of RHÖN-KLINIKUM AG are exposed in particular to the following risks: − Credit risk − Liquidity risk − Interest rate risk The aim of financial risk management is to limit the above risks through ongoing operating activities as well as the use of derivative and non-derivative (e.g. fixed-interest loans) financial instruments. As a general rule, derivative financial instruments may be entered into for hedging purposes, i.e. they are not used for trading or speculative purposes. As a rule, financial instruments for limiting the counterparty risk are entered into only with leading financial institutions with at least an investment grade rating. Financial risk management is conducted by the division Accounting, Tax, Controlling, Finance and Investor Relations under the supervi- sion of the CFO in line with the guidelines adopted by the Board of Management and the Supervisory Board. Risks are identified and measured by the Board of Management working together with the operative units of the Group. The CFO defines both the principles for interdivisional risk management and the guidelines for certain areas such as the management of interest rate and credit risks, the use of derivative and non-derivative financial instruments as well as the investment of liquidity surpluses. RHÖN-KLINIKUM AG | Annual Report 2023 101

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Critical estimates and assessments in accounting and valuation For the cash generating units, the recoverable amount is equal to the carrying amount as of an assumed cost of capital rate or an assumed EBIT discount: in % Units Frankfurt (Oder) RHÖN-KLINIKUM Campus Bad Neustadt Universitätsklinikum Gießen und Marburg Zentralklinik Bad Berka 3.2 Revenue recognition The Group generates revenues essentially from the provision of medical services. The hospitals of RHÖN-KLINIKUM AG, like all other hospitals in Germany, are subject to the statutory regulations on fees. Revenue recognition is essentially based on a comparison of perfor- mance and consideration under a contract: a service performed gives rise to an asset, the consideration received to an obligation. Treatment contracts between hospitals and patients or their health insurance funds correspond to contracts for services pursuant to section 630 a et seq. BGB. Irrespective of who performs the payment in future, it is normally the case that the patient will likely be regarded as the customer. The scope of the performance obligations in the context of hospital treatment is essentially governed by statutory provisions. The prices charged to the payers are stipulated by numerous laws and regulations. The patient receives and consumes the benefit simulta- neous with performance of the service. Control is thus transferred and also revenue recognised for a specified period. Revenues are recognised in accordance with progress of service performance over the service performance period. In order to create planning and revenue certainty, the remuneration regulations normally provide for prospective fee agreements. In practice, however, these negotiations take place only in the course of the financial year or even thereafter, creating uncertainties as to the service volume for which consideration is received at the balance sheet date. These are reflected in the balance sheet through objec- tive, reliable estimates of receivables or liabilities based on empirical values. Past experience has shown that the inaccuracies relating to Assumed cost of capital rate for 2023 Assumed cost of capital rate for 2022 Assumed EBIT discount for 2023 Assumed EBIT discount for 2022 9.4 7.1 7.7 17.2 13.4 7.4 7.4 17.7 38.0 14.0 22.0 69.0 53.0 11.0 11.0 67.0 the estimates are negligible for the Group’s financial position and results of operations. The Group generates its revenue for the most part from the statu- tory health insurance funds. As a general rule, the various budgets for the individual hospitals are defined together with the statutory health insurance funds at the beginning of each year. Diagnosis related groups (German Diagnosis Related Groups after stripping out nursing staff costs, aG-DRGs) are measured nationally on a uniform basis through the aG-DRG catalogue (output method as defined in IFRS 15). The measurement ratios are reviewed and adjusted each year by Institut für das Entgeltsystem im Krankenhaus GmbH (InEK). Personnel expense for bedside nursing are remunerated through separate nursing budgets. If the service volume invoiced by a hospital (number, severity or type of service) at the end the financial year does not correspond to the budget negotiated for that year, this results in either revenue surpluses or shortfalls that are compensated by way of income com- pensation between the health insurance funds and the respective hospital. If the actual volumes exceed or fall short of the agreed total budget, only the additional variable costs are paid or saved variable costs deducted, using fixed rates. The receivables or liabilities arising as a result are reported in the consolidated balance sheet and reve- nues are corrected accordingly. At the time the consolidated balance sheet was prepared, approved fee agreements existed at none of the hospitals with the exception of RHÖN-KLINIKUM AG; this meant that any compensation payments for excess revenues or shortfalls were estimated. In hospitals in which no fee agreements had yet been concluded for 2023 or for previous years, we adhered strictly to the legal framework in our accounting. We assume that the agreements for 2023 and for previous years will not have any negative impact on the result in 2024. RHÖN-KLINIKUM AG | Annual Report 2023 103

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Company acquisitions 4 | COMPANY ACQUISITIONS Consolidated companies The ultimate parent company is RHÖN-KLINIKUM Aktiengesellschaft with its registered office in Bad Neustadt a. d. Saale. The consolidated companies are as follows: Fully consolidated subsidiaries Companies consolidated using the equity method Other subsidiaries Consolidated companies 31 Dec. 2022 Additions Disposals 31 Dec. 2023 30 1 7 38 – – – 0 –3 – – –3 27 1 7 35 The disposals result from the conclusion of liquidations of three companies and their deletion from the company register in financial year 2023. These are the companies Wolfgang Schaffer GmbH i. L., RK Klinik Betriebs GmbH Nr. 35 i. L. and RK Reinigungsgesellschaft Nordost mbH i. L. Acquisition of doctor’s practices In financial year 2023, one doctor’s practice was acquired for consid- eration whose conditions of validity as per agreement were satisfied during the reporting period of 2023. Consolidation in the Group also took place in financial year 2023. No costs were incurred from the acquisition of this doctor’s practice. The revenues and annual results generated since their inclusion in the consolidated statements are of minor importance for the Group of RHÖN-KLINIKUM AG. The final purchase price allocation has the following impact on the Group’s net assets in 2023: in € million Purchase of doctor's practices, January to December 2023 Acquired assets and liabilities Intangible assets Property, Plant and Equipment Other liabilities Net assets acquired + Goodwill Cost ./. Purchase price payments outstanding ./. Acquired cash and cash equivalents Cash outflow on transaction Fair value post acquisition 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.0 0.2 Goodwill amounting to €0.1 million essentially includes synergy effects expected from the expansion of medical care centres. The goodwill recognised is likely to be tax-deductible. RHÖN-KLINIKUM AG | Annual Report 2023 105

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement 5.2 Other income Other operating income comprises: in € million Income from services rendered Income from grants and other allowances Income from indemnification payments/ other reimbursements Other 2023 2022 218.2 37.4 1.7 15.1 272.4 194.4 13.3 1.8 10.6 220.1 Income from services rendered includes income from ancillary and incidental activities amounting to €208.5 million (previous year: €185.7 million) as well as income from rental and lease agreements amounting to €9.7 million (previous year: €8.7 million). 5.3 Materials and consumables used in € million Cost of raw materials, consumables and supplies Cost of purchased services 2023 2022 438.5 50.0 488.5 400.5 46.1 446.6 As a result of higher purchasing prices, materials and consumables used witnessed an increase, disproportionate to the rise in revenues, by €41.9 million or 9.4% in financial year 2023 compared with the same period of the previous year. The cost-of-materials ratio climbed from 30.9% to 33.4%. 5.4 Employee benefits expense The Group received grants and other allowances as compensation for certain purpose-tied expenses in connection with publicly funded measures (e.g. costs of personnel and materials for research and teaching). in € million The rise in other income by €52.3 million or 23.8% is mainly attrib- utable to the higher income from ancillary and incidental activities resulting among other things from higher sales of drugs and cytostat- ics. Moreover, reimbursements in connection with the compensation for higher energy expenses from funds of the Health Fund (Gesund- heitsfonds) within the meaning of section 26 f KHG were included at €29.9 million (previous year: €2.0 million). During the previous year, this item most recently still included €3.2 million in reimbursements from the legislator in connection with the COVID-19 pandemic. Also included in other income item is an amount of €5.0 million in reversals of liabilities from previous years recognised in the income statement. Wages and salaries Social insurance contributions Expenditure for post-employment benefits Defined contribution plans Defined benefit plans 2023 2022 818.5 69.9 85.7 0.3 974.4 793.3 68.0 88.2 0.3 949.8 Expenses for defined contribution plans concern the statutory pension insurance agency, payments to the federal and state pension scheme (VBL) and to Bayerische Versorgungskammer- Zusatzversorgung (BVK). As in the previous year, the defined benefit plans relate to the benefit commitments of Group companies, and comprise commitments for retirement pensions, invalidity pensions and pensions for surviving dependants as well as severance payments for one member of the Board of Management and one other exec- utive employee after termination of the employment relationship. RHÖN-KLINIKUM AG | Annual Report 2023 107

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement 5.9 Finance result – net The finance result is shown as follows: in € million Result of investments accounted for using the equity method Income of investments accounted for using the equity method Expense of investments accounted for using the equity method Finance income Bank balances Interest income from tax assets Other interest income Finance expenses Liabilities to banks Interest expenses from tax liabilities Other interest expenses Result of impairment on financial investments as defined in IFRS 9 Income from impairment on financial investments Expense from impairment on financial investments 2023 2022 0.0 – 0.0 8.9 1.5 0.1 10.5 –3.1 0.0 –0.6 –3.7 0.5 – 0.5 7.3 0.1 – 0.1 1.1 0.0 0.2 1.3 –2.3 –0.9 –0.9 –4.1 0.2 – 0.2 –2.5 In financial year 2023, the finance result improved from –€2.5 million by €9.8 million to +€7.3 million in particular thanks to a positive development of interest rates. Income from impaired financial assets under IFRS 9 was recognised in the finance result in the amount of €0.5 million (previous year: €0.2 million). The net interest income under IFRS 9 for financial assets and liabilities which are not included in the category “financial assets and liabilities shown at fair value in profit and loss” amounted to €6.6 million (income) in financial year 2023 (previous year: expense of €3.0 million). The amount comprises income of €9.6 million (pre- vious year: €1.3 million) and expenses of €3.0 million (previous year: €4.3 million). 5.10 Income taxes Income taxes consist of the corporate income tax including the sol- idarity surcharge, and to a lesser extent of trade tax. This item also includes deferred taxes resulting from differences between the IFRS and tax balance sheets as well as from consolidation adjustments and expected realisable tax loss carry-forwards which, as a rule, have no expiry date. Income tax comprises the following: in € million Current income tax Deferred taxes 2023 2022 6.8 0.8 7.6 6.0 0.7 6.7 At an unchanged tax rate, the tax expense item saw an increase compared with the same period last year by €0.8 million due to a higher tax assessment basis. The income tax burden stands at 15.9% (previous year: 20.0%). RHÖN-KLINIKUM AG | Annual Report 2023 109

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6 | NOTES TO THE CONSOLIDATED BALANCE SHEET in € million 6.1 Goodwill and other intangible assets Other intangible assets Goodwill Cost 1 Jan. 2022 Total Changes in consolidated companies 165.5 61.8 227.3 Additions Disposals Reclassifications 31 Dec. 2022 Other intangible assets Goodwill Total 165.2 59.3 224.5 0.3 0.0 0.0 0.0 0.0 2.4 0.0 0.1 0.3 2.4 0.0 0.1 165.5 61.8 227.3 in € million Cost 1 Jan. 2023 Changes in consolidated companies Additions Disposals Reclassifications 31 Dec. 2023 0.1 0.0 0.2 0.0 165.4 0.0 1.7 0.9 –0.4 62.2 47.9 4.8 0.9 –0.1 51.7 10.5 0.1 1.7 1.1 –0.4 227.6 47.9 4.8 0.9 –0.1 51.7 175.9 Cumulative depreciation and impairment 1 Jan. 2023 Depreciation Disposals Reclassifications 31 Dec. 2023 Balance sheet value as at 31 December 2023 0.0 0.0 0.0 0.0 0.0 165.4 Cumulative depreciation and impairment 1 Jan. 2022 Depreciation Disposals Reclassifications 31 Dec. 2022 Balance sheet value as at 31 December 2022 0.0 0.0 0.0 0.0 0.0 165.5 42.9 5.0 0.0 0.0 47.9 13.9 42.9 5.0 0.0 0.0 47.9 179.4 The item “Other intangible assets” primarily includes software. There are no restrictions on title and/or other rights related to the assets. Goodwill is subjected to an annual impairment test for its respective cash generating unit (each hospital with its inpatient, semi-inpatient and outpatient care structures, unless the related goodwill of coop- erating units is monitored at a higher level). This impairment test is performed on 1 October of each year. RHÖN-KLINIKUM AG | Annual Report 2023 111

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The weighted cost of capital of a potential investor from the health- care sector is used as the discount rate at the time of measurement, taking into account the tax shield arising from theoretical debt financ- ing (“tax shield”). This discount rate was defined at 6.24% for 2023 (previous year: 6.78%). Significant goodwill relates to the following cash generating units: The table below shows the assumptions of flat rate growth rates for revenues by which the company planning is projected by a further five years which were used in the impairment test of the units with allocated goodwill to which material goodwill was attributed to determine the value in use: in € million Units in % 31 Dec. 2023 31 Dec. 2022 Universitätsklinikum Gießen und Marburg Zentralklinik Bad Berka RHÖN-KLINIKUM Campus Bad Neustadt Other goodwill of less than €5.0 million 137.5 16.4 6.5 5.0 137.5 16.6 6.5 4.9 Balance sheet value 165.4 165.5 For the calculation of value in use of the business generating units, cash flows were forecast on the basis of past experience, current operating results and best-possible estimates of future management performance as well as market assumptions. The value in use is primarily defined by the terminal value (present value or perpetual annuity) which is particularly sensitive to changes in assumptions for the long-term EBIT margin and the discount rate. Whereas the discount rate was defined uniformly for all units with allocated goodwill, the EBIT margin is calculated individually for each unit. The discount rate reflects the current market assessment of the entities’ specific risks. The EBIT margins take account of external mac- ro-economic data and sector-specific trends. For planning purposes, the units accounting for the main portion of goodwill are assumed to have a homogenous structure. 2023 2022 Flat rate growth rate – revenues 3.00 3.00 Flat rate growth rate – revenues 3.00 3.00 WACC 6.24 6.24 WACC 6.78 6.78 3.00 6.24 3.00 6.78 Universitäts- klinikum Gießen und Marburg Zentralklinik Bad Berka RHÖN-KLINIKUM Campus Bad Neustadt The assumptions for the other units with allocated goodwill are comparable. The values of revenues in the ten-year planning period of the groups of cash generating units to which material goodwill was attributed are based on average organic growth rates of between 3.2% and 3.6% (previous year: 2.8% and 3.4%). In connection with the impairment test, a sensitivity analysis was also performed. Within the test the following assumptions were used: − EBIT declines by 10% − WACC increase by 0.5% As a result of the sensitivity analysis it was determined that a decline in EBIT by 10% does not result in any impairment requirement (previ- ous year: no impairment requirement). An increase in WACC by 0.5% likewise does not give rise to an impairment requirement (previous year: no impairment requirement). RHÖN-KLINIKUM AG | Annual Report 2023 113

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet Buildings, technical equipment and medical equipment include as at 31 December 2023 rights of use pursuant to IFRS 16 in which the Group is the lessee. The rights of use are as follows: in € million Cost 1 Jan. 2023 Addition to consolidated companies Additions Disposals 31 Dec. 2023 Cumulative depreciation and impairment 1 Jan. 2023 Depreciation Disposals 31 Dec. 2023 Balance sheet value as at 31 December 2023 in € million Cost 1 Jan. 2022 Addition to consolidated companies Additions Disposals Reclassifications 31 Dec. 2022 Cumulative depreciation and impairment 1 Jan. 2022 Depreciation Disposals Reclassifications 31 Dec. 2022 Balance sheet value as at 31 December 2022 Land and buildings Operating and office equipment 6.5 0.0 0.0 0.2 6.3 2.6 0.9 0.1 3.4 2.9 13.0 0.0 2.6 3.0 12.6 8.6 2.2 2.3 8.5 4.1 Land and buildings Operating and office equipment Total 19.5 0.0 2.6 3.2 18.9 11.2 3.1 2.4 11.9 7.0 Total 5.6 0.0 1.0 0.1 0.0 6.5 1.8 0.9 0.1 0.0 2.6 3.9 13.4 19.0 0.0 0.8 1.2 0.0 0.0 1.8 1.3 0.0 13.0 19.5 7.2 2.4 1.0 0.0 8.6 4.4 9.0 3.3 1.1 0.0 11.2 8.3 115 Whereas during the same period of the previous year borrowing costs of €0.8 million were recognised that related to financing the acquisition or production of qualifying assets and were recognised in additions to property, plant and equipment, no such borrowing costs that would have required recognition were incurred during the reporting year on account of the positive interest result. In the previous year an average interest rate of 1.9% was used, which reflects the Group’s general costs of borrowing from banks. Similar to the previous year, the Group has no registered charges on real property as collateral for bank loans. Public grants related to assets are deducted from the cost of the asset for which they are given, reducing the depreciation over the period. The deducted amortised amount of assistance granted under hospital financing legislation and which was invested in line with the appli- cable conditions totals €146.8 million (previous year: €144.5 million). To secure conditionally repayable single grants under the KHG (e.g. for the construction of new hospitals or major extensions) totalling €1.3 million (previous year: €1.5 million), the Group holds regis tered charges on real property in the amount of €9.6 million (previous year: €4.1 million). There are no reasons to assume that these grants will have to be repaid. RHÖN-KLINIKUM AG | Annual Report 2023

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.4 Financial investments accounted for using the equity method Other financial assets (non-current) 6.5 Other non-current financial assets break down as follows: 6.4.1 Investments accounted for using the equity method As in the previous year, one joint venture was measured in the con- solidated financial statements using the equity method: in € million Registered office Share in % Participating interests 31 Dec. 2023 31 Dec. 2022 12.7 12.7 13.3 13.3 Name of company Joint ventures Energiezentrale Universitätsklinikum Gießen GmbH Giessen 50.0 6.4.2 Joint ventures The object of enterprise of the joint venture is to carry on, together with Stadtwerke Gießen, the supply of energy to the university hos- pital in Giessen. In addition to RHÖN-KLINIKUM AG with an interest of 50%, Stadtwerke Gießen AG holds an interest of 50% in the joint venture. The table below provides a summary of the aggregated results data and aggregated carrying amounts of the joint venture accounted for using the equity method: in € million Results data and carrying amounts of joint venture accounted for using the equity method Revenues Earnings after tax Pro rata earnings after tax Pro rata total comprehensive income after tax Carrying amount of joint venture accounted for using the equity method 2023 2022 0.4 0.0 0.0 0.0 0.5 0.4 0.2 0.1 0.1 0.5 As at the balance sheet date, the joint venture reports assets of €1.1 million (previous year: €1.1 million) as well as equity of €1.1 million (previous year: €1.0 million). The equity interests relate to equity interests held by the company RHÖN-Innovations GmbH in the companies Inovytec Medical Solutions Ltd., Telesofia Medical Ltd. and CLEW Medical Inc. The interests are measured at fair value in accordance with IFRS 9. The equity interests are measured at fair value directly in equity (fair value through other comprehensive income, without recycling). The carry- ing amount of €12.7 million (previous year: €13.3 million) corresponds to the maximum default risk. Moreover, €0.0 million (previous year: €0.0 million) relates to immate- rial equity interests which are measured at fair value. Like at the previous year’s balance sheet date, no long-term fixed deposit investments and according no impairments were to be recognised according to IFRS 9 at the balance sheet date of 31 December 2023. Inventories 6.6 Inventories in the amount of €34.2 million (previous year: €33.3 million) are attributable to raw materials, consumables and supplies and mainly consist of medical supplies. Impairments of €3.8 million (previous year: €3.7 million) were effected. All invento- ries are owned by RHÖN-KLINIKUM AG and the companies affiliated with RHÖN-KLINIKUM AG. There are no assignments or pledges of inventories. RHÖN-KLINIKUM AG | Annual Report 2023 117

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.8 Other financial assets (current) Other financial assets (current) attributable to fixed deposits, as well as corresponding impairments within the meaning of IFRS 9 were divided into the following rating classes as at 31 December 2022: in € million Time deposit < 1 year Receivables under the KHEntgG Remaining other financial assets 31 Dec. 2023 31 Dec. 2022 in € million < 1 year < 1 year 136.8 150.5 10.0 297.3 219.0 105.1 8.6 332.7 Impairment matrix according to S&P rating classes 31 Dec. 2022 A BBB Total Gross carrying amount Expected credit loss 145.0 75.0 220.0 0.5 0.5 1.0 The remaining other financial assets (current, not including fixed deposits) as well as the corresponding impairments within the mean- ing of IFRS 9 show the following maturity structure as at the balance sheet date of 31 December 2023: in € million Impairment matrix 31 Dec. 2023 Not overdue Between 0 and 30 days overdue Between 31 and 90 days overdue Between 91 and 180 days overdue More than 180 days overdue Gross carrying amount Expected credit loss 160.0 0.6 0.1 0.1 0.2 161.0 0.3 0.1 0.0 0.0 0.1 0.5 Receivables under the German Hospital Remuneration Act (Kranken- hausentgeltgesetz, KHEntgG) relate to compensation claims under federal hospital compensation legislation (Hospital Remuneration Act (Krankenhausentgeltgesetz, KHEntgG)) and the Federal Hospital Nursing Rate Ordinance (Bundespflegesatzverordnung, BPflV) as well as compensation claims against the training fund. The COVID-19 pan- demic is still resulting in delays in budget negotiations, especially for the nursing budget. Remaining other financial assets relate among others to receivables from services rendered which are not primarily related to patient treatments at hospitals (€8.5 million, previous year: €7.0 million), receivables due from employees in particular from invoices as part of the liquidation right of head physicians (€1.9 million, previous year: €1.9 million), receivables relating to training of emergency paramedics (€0.5 million, previous year €0.5 million), as well as trade receivables (€0.5 million, previous year: €0.5 million). Other financial assets include impairments amounting to €1.7 million (previous year: €1.8 million). No reversals of impairment losses were made. Other financial assets (current) attributable to fixed deposits, as well as corresponding impairments within the meaning of IFRS 9 are divided into the following rating classes as at 31 December 2023: Total in € million Impairment matrix according to S&P rating classes 31 Dec. 2023 A BBB Total Gross carrying amount Expected credit loss 132.3 5.0 137.3 0.5 0.0 0.5 RHÖN-KLINIKUM AG | Annual Report 2023 119

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.11 Cash and cash equivalents in € million Cash with banks and cash on hand Short-term bank deposits 31 Dec. 2023 31 Dec. 2022 181.0 25.0 206.0 77.3 0.0 77.3 6.12 Equity The registered share capital of RHÖN-KLINIKUM AG was €167,406,175 (previous year: €167,406,175). It is divided into 66,962,470 (previous year: 66,962,470) fully paid-up non-par value bearer shares each with a notional value in the registered share capital of €2.50 per share. Arithmetic share in registered share capital in € Number The increase in cash with banks and cash on hand is attributable to higher interest rates for short-term investments resulting from a shift in the interest rate curve with higher short-term interest rates and lower long-term interest rates. As far as possible, freely disposable funds were re-allocated at matching maturities into fixed deposit investments with a remaining term of < 1 year (> 3 months) and reported under the item “Other financial assets (current)”. Due to the shift in the interest rate curve, bank balances, including commer- cial paper, were concluded with an initial term of < 3 months. The effective interest rate for these bank balances is 4.03%. The average remaining term of these deposits was 20 days. Ordinary shares as at 1 January 2023 66,962,470 167,406,175 Change in 2023 – – Ordinary shares as at 31 December 2023 66,962,470 167,406,175 The premium from the capital increase in the amount of €396.0 million (previous year: €396.0 million) as well as the amounts of €178.2 million (previous year: €178.2 million) attributable to the shares redeemed in the previous years are reported in the capital reserve. The high level of cash with banks and cash on hand ensures flexibility in controlling cash outflows in connection with extensive construc- tion measures. The item includes demand deposits with restricted use in the amount of €25.8 million (previous year: €18.0 million). Other reserves at the balance sheet date amounting to €510.5 million (previous year: €482.3 million) comprise earnings generated in prior years of companies included in the consolidated annual report amounting (to the extent not paid out to shareholders) in the amount of €510.5 million (previous year: €482.3 million) as well as effects of consolidation adjustments. Cash and bank overdrafts are aggregated as follows for the purpose of the statement of cash flows: in € million Cash and cash equivalents Bank overdrafts Cash position 31 Dec. 2023 31 Dec. 2022 206.0 0.0 206.0 77.3 0.0 77.3 The total result (sum of consolidated profit and other earnings) for financial year 2023 stands at €39.7 million (previous year: €27.3 million). This includes gains from the revaluation of defined benefit pension plans amounting to €0.1 million after tax (previous year: €0.1 million) as well as losses from changes in the fair value of equity investments in the amount of €0.5 million (previous year: €0.3 million). RHÖN-KLINIKUM AG | Annual Report 2023 121

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The contractual interest adjustment dates relating to the interest-bearing liabilities are as follows: in € million Fixed interest period ends Liabilities to lenders 2024–2027 2028 2029 > 2029 Interest on loans 1 Weighted interest rate. 31 Dec. 2023 31 Dec. 2022 Interest rate1 in % Nominal amount Carrying amount of loans Interest rate1 in % Nominal amount Carrying amount of loans 1.33 1.82 – 2.35 31.0 52.0 – 60.0 30.9 51.9 – 58.9 1.0 1.26 1.82 – 2.35 38.0 52.0 – 60.0 37.9 51.8 – 58.9 1.0 143.0 142.7 150.0 149.6 The effective interest rates at balance sheet date are: in % 31 Dec. 2023 31 Dec. 2022 Liabilities to banks 1.98 1.89 The remaining terms of the financial liabilities are: in € million Up to 1 year Between 1 and 5 years More than 5 years Total 31 Dec. 2023 31 Dec. 2022 1.0 82.8 58.9 142.7 8.0 30.9 110.7 149.6 As in the previous year, the financial liabilities stated are not secured by registered charges on real property. 6.14 Provisions for post-employment benefits The Group provides post-retirement benefits for eligible employees under its company pension scheme, which comprises both defined benefit and defined contribution pension plans. Obligations under this scheme include current pension payments as well as future pension entitlements. Defined benefit obligations are financed by recognising provisions. Amounts relating to defined contribution plans are recognised imme- diately in profit or loss. One member of the Board of Management and one further senior executive (previous year: one member of the Board of Management and one further senior executive) are covered by a plan providing for post-retirement benefits. In addition to their regular remuneration these persons, on termination of their employment as members of the Board of Management, receive a post-retirement benefit calcu- lated on the basis of the length of service and level of remuneration and not exceeding 1.5 times the last annual remuneration. The scope of the obligation was calculated based on the individual contract terms and not on a uniform retirement age as with the other pension plans. In this connection there are risks associated with changes in the assessment basis. These essentially relate to the dependence on the last salary and last variable remuneration components. If the development of this assessment basis turns out to be different from what is assumed in the provision calculations, this might give rise to a subsequent financing requirement. RHÖN-KLINIKUM AG | Annual Report 2023 123

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.15 Other provisions Other provisions developed as follows in the financial year: in € million Recovery risks Liability risks Other risks 31 Dec. 2022 18.4 13.9 1.7 34.0 Use 13.6 0.2 0.0 13.8 Re- classification Reversal Allocation 31 Dec. 2023 of which < 1 year of which > 1 year 0.0 0.0 10.0 10.0 0.0 0.0 5.6 5.6 12.1 3.0 0.0 15.1 16.9 16.7 6.1 39.7 16.9 16.7 1.1 34.7 0.0 0.0 5.0 5.0 The provisions for recovery risks are provisions for risks of audits outstanding of the Medical Review Board of the Statutory Health Insurance Funds (Medizinischer Dienst der Krankenversicherung, MDK). The provisions for liability risks relate to claims for damages by third parties. These compare with repayment claims from insurers in the amount of €6.8 million (previous year: €5.3 million); these are shown under other assets (current). In the assessment of the Board of Management, the settlement of these liability cases using the pro- visions will not entail any significant additional expenses. The timing of cash outflows from liability risks, which generally may occur in the short term, essentially depends on the course and outcome of specific liability cases. The other risks include provisions for risks in connection with invest- ment obligations in the amount of €5.0 million. The investment proj- ects concerned were modified in financial year 2023 and the periods for meeting the investment obligations adjusted. As a result of the higher uncertainties in estimates, obligations recognised in previous years were reclassified from non-current other financial liabilities to non-current other provisions. The further amounts recognised under other risks mainly relate to provisions formed for legal and non-income-tax risks in the amount of €0.9 million (previous year: €1.5 million) which are current in nature. Compared with the previous year, the maturities of other provisions are as follows: in € million Recovery risks Liability risks Other risks 31 Dec. 2023 of which < 1 year of which > 1 year 31 Dec. 2022 of which < 1 year of which > 1 year 16.9 16.7 6.1 39.7 16.9 16.7 1.1 34.7 0.0 0.0 5.0 5.0 18.4 13.9 1.7 34.0 18.4 13.9 1.7 34.0 0.0 0.0 0.0 0.0 The Group of RHÖN-KLINIKUM AG has contingent liabilities of up to a maximum rounded amount of €0.0 million (previous year: €0.0 million). These constitute liabilities as part of the performance process. At the present time RHÖN-KLINIKUM AG does not expect any significant usage in future. RHÖN-KLINIKUM AG | Annual Report 2023 125

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.18 Other liabilities in € million 31 Dec. 2023 31 Dec. 2022 < 1 year > 1 year < 1 year > 1 year 81.8 99.2 13.3 3.7 0.5 14.0 0,0 0.0 0.0 0.0 0.0 0.0 79.4 48.8 13.6 3.4 0.6 10.6 0.0 0.0 0.0 0.0 0.0 0.0 212.5 0.0 156.4 0.0 Personnel liabilities Liabilities under KHG Operating taxes and social security contributions Deferred income Prepayments Other liabilities Other liabilities (non-financial instruments) Payroll liabilities relate in particular to results-based remuneration, target agreements, obligations arising from holiday leave not taken as well as overtime obligations, standby services and anniversaries. Moreover, severance payment obligations are recognised under this item. Liabilities under the KHG relate to government grants not yet used in accordance with the conditions for their use granted under state hospital financing legislation in the amount of €38.4 million (previ- ous year: €32.9 million), funds from the German Hospital Future Act (Krankenhauszukunftsgesetz, KHZG) in the amount of €22.3 million (previous year: €15.9 million) as well as funds from the Future Agree- ment Plus (Zukunftsvereinbarung Plus) with Universitätsklinikum Gießen und Marburg in the amount of €38.5 million (previous year: €0.0 million). The remaining liabilities essentially include third-party funds from, among other things, ongoing studies not yet appropriated, as well as advance payments in connection with compensation for higher energy expenses from funds of the Hospital Fund. 6.19 Current income tax liabilities Current income tax liabilities in the amount of €8.8 million (previ- ous year: €11.2 million) comprise corporate income tax, solidarity surcharge and trade tax not yet assessed for the past financial year and previous years. 6.20 Derivative financial instruments As at the previous year’s balance sheet date, no derivative financial instruments exist. RHÖN-KLINIKUM AG | Annual Report 2023 127

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 31 Dec. 2023 Financial Instruments 31 Dec. 2022 Financial Instruments of which of which Carrying amount Fair value Carrying amount Fair value 12.7 12.7 0.0 0.0 526.8 206.0 141.8 12.2 7.8 4.4 66.8 1.0 11.5 8.8 2.7 12.7 12.7 0.0 0.0 526.8 206.0 141.8 12.2 7.8 4.4 66.8 1.0 11.5 8.8 2.7 732.8 12.7 0.0 226.2 12.7 12.7 0.0 0.0 526.8 206.0 124.4 7.7 7.7 – 66.8 1.0 8.7 8.7 – 732.8 12.7 0.0 208.6 13.3 13.3 0.0 0.0 561.3 77.3 141.7 20.2 14.6 5.6 70.0 8.0 11.6 8.7 2.9 13.3 13.3 0.0 0,0 561.3 77.3 141.7 20.2 14.6 5.6 70.0 8.0 11.6 8.7 2.9 638.6 13.3 0.0 243.0 13.3 13.3 0.0 0.0 561.3 77.3 119.6 14.4 14.4 – 70.0 7.8 8.6 8.6 – 638.6 13.3 0.0 220.4 RHÖN-KLINIKUM AG | Annual Report 2023 129

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.21.2 Net gains or losses by measurement category The net result (expense) by measurement category according to IFRS 9 for financial year 2023 is as follows: in € million Financial assets measured at amortised cost Total From subsequent measurement From share price gains At fair value Impairment 0.0 0.0 0.0 0.0 –0.1 –0.1 Net result 2023 4.3 4.3 From disposal 4.4 4.4 The net result (expense) by measurement category according to IFRS 9 for financial year 2022 is as follows: in € million Financial assets measured at amortised cost Total From subsequent measurement Net result From share price gains At fair value Impairment 0.0 0.0 0.0 0.0 –0.2 –0.2 From disposal 13.2 13.2 2022 13.0 13.0 6.21.3 Financial liabilities (maturity analysis) The following table sets out the contractually agreed (undiscounted) interest payments and redemption payments of the original financial liabilities: in € million Financial liabilities – promissory note Financial liabilities – registered bond Trade payables Other financial liabilities/ other provisions Liabilities under leases Cash outflows 2024 2025–2030 > 2030 –1.4 –87.1 0.0 –72.7 0.0 0.0 0.0 –1.4 –66.8 –8.8 –2.8 –81.2 –8.5 0.0 –7.9 –4.5 –108.0 –72.7 RHÖN-KLINIKUM AG | Annual Report 2023 131

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Statement of cash flows The €17.1 million increase in cash used in financing activity results from the repayment of the first tranche of the promissory note in the amount of €7.0 million as well as from the dividend distributed in June 2023 to the shareholders of RHÖN-KLINIKUM AG in the amount of €10.0 million. The statement of cash flows sets out the change in cash and cash equivalents between two balance sheet dates. In the RHÖN-KLINIKUM Group, this item exclusively comprises cash and cash equivalents attributable to continuing operations because no operations were discontinued. In financial year 2023, financial liabilities changed as follows: in € million 31 Dec. 2022 Cash changes Non-cash changes Change in consolidated companies 31 Dec. 2023 Lease obligations Current financial liabilities Non-current financial liabilities Total liabilities from finance activities 8.5 8.0 141.6 158.1 –3.3 –7.0 – –10.3 1.9 – 0.2 2.1 – – – 0.0 7.1 1.0 141.8 149.9 Financial liabilities changed in financial year 2022 as follows: in € million 31 Dec. 2021 Cash changes Non-cash changes Change in consolidated companies 31 Dec. 2022 Lease obligations Current financial liabilities Non-current financial liabilities Total liabilities from finance activities 10.2 1.0 148.5 159.7 –3.5 –1.0 – –4.5 1.8 8.0 –6.9 2.9 – – – 0.0 8.5 8.0 141.6 158.1 RHÖN-KLINIKUM AG | Annual Report 2023 133

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Shareholdings | Other disclosures in € ´000 Interest held in % Result for the year Equity 9 | OTHER DISCLOSURES 9.1 Average annual number of employees Other companies/shelf companies Energiezentrale Universitätsklinikum Gießen GmbH, Giessen Kinderhort Salzburger Leite gemeinnützige Gesellschaft mbH, Bad Neustadt a. d. Saale KLINIK "HAUS FRANKEN" GMBH Bad Neustadt/Saale i. L., Bad Neustadt a. d. Saale Marburger Ionenstrahl-Therapie Betriebs-Gesellschaft mbH, Bad Neustadt a. d. Saale Psychosomatische Klinik GmbH Bad Neustadt/Saale, Bad Neustadt a. d. Saale PTZ GmbH, Marburg RHÖN-KLINIKUM Energie für Gesundheit GmbH, Bad Neustadt a. d. Saale1 RHÖN-Innovations GmbH, Bad Neustadt a. d. Saale 50.0 1,065 100.0 100.0 181 691 40 –2 13 100.0 –34,045 1,648 100.0 100.0 5 306 100.0 1,500 –8 –2 0 Medical doctors Nursing services Medical-technical services Functional Supply and misc. services Technical Administrative Other personnel 2023 2022 Change Number1 Number1 Number1 in % 1,087 5,377 2,551 1,575 1,820 262 1,069 5,260 2,542 1,581 1,816 261 1,040 1,008 309 303 18 117 9 –6 4 1 32 6 14,021 13,840 181 1.7 2.2 0.4 –0.4 0.2 0.4 3.2 2.0 1.3 100.0 5.562 698 1 Headcount, excluding board members, managing directors, apprentices, trainees, those in alternative national service and civil servants. 1 The company claims the exemptions pursuant to section 264 (3) HGB from preparing notes and, to the extent required by law, from preparing a management report as well as disclosure. 9.2 Other financial obligations 8.2 Other companies according to section 313 (2) No. 2 et seq. HGB in € million 31 Dec. 2023 31 Dec. 2022 in € ´000 Order commitments 37.0 22.0 Interest held in % Result for the year Equity Other 4QD – Qualitätskliniken.de GmbH, Berlin1 20.0 309 0.1 6.4 Bäderland Bayerische Rhön GmbH & Co. KG, Bad Kissingen1 CLEW Medical Inc., Delaware (USA)2 HOSPIZ MITTELHESSEN gemeinnützige GmbH, Wetzlar1 Inovytec Medical Solutions Ltd., Hod Hasharon (Israel)2 Seniorenpflegeheim GmbH Bad Neustadt a. d. Saale, Bad Neustadt a. d. Saale1 Telesofia Medical Ltd., Tel Aviv (Israel)2 25.0 9.9 –479 –391 –1,769 –342 1 Figures according to annual financial statements of 31 December 2022. 2 Figures according to annual financial statements of 31 December 2022, converted at closing/ average exchange rate on 31 December 2023. Due in subsequent year Due in 2 to 5 years Due in 5 years Total other 0 5 45.7 20.7 0.5 66.9 41.4 15.5 1.4 58.3 20 1,761 –5,302 13.6 548 6 9.2 5,694 –3,260 Of the figure for order commitments, €3.3 million (previous year: €1.7 million) is attributable to intangible assets, and €21.6 million (previous year: €10.9 million) to property, plant and equipment. The remaining other financial obligations are mainly attributable to service agreements (maintenance agreements, agreements con- cerning the sourcing of products, agreements relating to laundry services, etc.). As at the balance sheet date, there are no obligations under loan commitments to associates (previous year: no obligations). RHÖN-KLINIKUM AG | Annual Report 2023 135

Investment property 9.3.2 The Group lets residential space to employees, office and commercial space to third parties (e.g. cafeteria), as well as premises to doctors cooperating with the hospital and to joint laboratories as part of cancellable operating leases. The most significant operating lease contracts by amount stem from the letting of property to third parties. The largest item in absolute terms was the letting of a property to a nursing home operator. Based on the provisions of IFRS 13.97, fair value is calculated for the assets to be stated according to IAS 40. The fair value determined in this regard cannot be observed on an active market nor can be derived from a quoted market price and are thus classified to Level 3 of the fair value hierarchy of IFRS 13. The fair value is determined using a capitalised value approach in which the corresponding components of the income cost approach such as gross profit, expected return on land value and standard land value are used as input factors. On the basis of the capitalised value of potential earnings, no material differences between the fair value of the properties and their carrying amounts shown below are seen. For this reason, no external fair-value expertise was obtained. Since the lease agreement was terminated by the operator of the retirement and nursing home in financial year 2021, the useful life was adjusted in the previous year to the termination notice period. The lease agreement expired at the end of April 2023. Rental income of €0.1 million (previous year: €0.4 million) was generated in financial year 2023. Based on the higher depreciation, the operating costs for the investment properties amounted to €0.3 million in the financial year (previous year: €1.0 million). As part of the subsequent use of the building as a residence for employees for hospital operations, the carrying amounts in financial year 2023 were reclassified to property, plant and equipment. They are accounted for entirely by properties with which rental income was generated. CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures in € million Cost 1 Jan. Additions Disposals Reclassifications 31 Dec. Cumulative depreciation 1 Jan. Depreciation Disposals Reclassifications 31 Dec. Balance sheet value as at 31 Dec. 2023 2022 Total Total 5.0 0.0 0.0 –5.0 0.0 4.7 0.3 0.0 –5.0 0.0 0.0 5.0 0.0 0.0 0.0 5.0 3.7 1.0 0.0 0.0 4.7 0.3 There is also income from non-terminable leases. The minimum lease payments to be received in future within one year are €0.9 million (previous year: €0.7 million). The minimum lease payments for the period of one to five years are €1.5 million (previous year: €1.6 million) and those having a maturity date exceeding five years are €0.7 million (previous year: €1.0 million). 9.4 Related parties According to the definition of IAS 24.9, related parties are those related to the reporting entity. Such parties are in particular natural persons who control the reporting entity or are involved in its joint management, exercise a material influence or hold a key position in the corporate management of the reporting entity. The same is true of close relatives of such persons. A person’s close relatives are family members who may be assumed to be capable of influencing such person or being influenced by such person in their transactions with the Company. That includes children and spouses of life partners of such person, children of the spouse of life partner of such person, and dependants of such person or of the spouse of life partner of such person. Also included are companies of the same corporate group and companies subject to or exercising a material influence. RHÖN-KLINIKUM AG | Annual Report 2023 137

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures In the year under review, members of the Supervisory Board of RHÖN-KLINIKUM AG, or companies and entities related with these as well as companies within the meaning of IAS 24, rendered the following services at arm’s length terms: in € ´000 Related party Companies as defined by IAS 24 Nature of services Dr Bernard große Broermann or his heirs Asklepios Kliniken Group of which Asklepios Kliniken GmbH & Co. KGaA Peter Berghöfer Hafid Rifi Marco Walker Regina Dickey Dr Cornelia Süfke Dr Jan Liersch (from 23 September 2022) Prof. Dr Bernd Griewing Eugen Münch Purchase of services and medical products Purchase of services and medical products Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Employee expenses, medical treatments Fee for services As in the previous year, the expenses were recognised in the income statement under the item “Materials and consumables” as well as the item “Other expenses”. As in the previous year, no impairments were to be recognised in financial year 2023. The following services were recognised in the income statement under other income: in € ´000 Related party Companies as defined by IAS 24 Nature of services Dr Bernard große Broermann or his heirs Eugen and Ingeborg Münch Dr Stefan Stranz Asklepios Kliniken Group of which Asklepios Kliniken GmbH & Co. KGaA Services, pharmacy services and medical products Services, medical products and other Telephone costs, medical services Services RHÖN-KLINIKUM AG | Annual Report 2023 Expenses 2023 2022 10,346 1,872 8,519 2,773 4 7 3 3 4 4 4 2 3 4 3 1 1,203 643 207 693 Income 2023 2022 12,622 6,550 1,162 1 0 0 14 2 139

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures 9.5 Total payments of Supervisory Board, the Board of Management and the Advisory Board The total expenditures (excluding VAT) for members of the Supervi- sory Board are broken down below: in € ´000 Total payments Dr Jan Liersch Georg Schulze Hafid Rifi Peter Berghöfer Nicole Mooljee Damani (until 8 January 2022) Dr Julia Dannath-Schuh Regina Dickey Peter Ducke Prof. (apl.) Dr med. Leopold Eberhart Irmtraut Gürkan Kai Hankeln Dr med. Martin Mandewirth PD Dr med. Thomas Pillukat Christine Reißner Oliver Salomon Dr Cornelia Süfken (from 2 March 2022) Marco Walker As at the balance sheet date, liabilities to members of the Supervisory Board in the amount of €0.6 million (previous year: €0.6 million) exist. 2023 2022 102 107 60 69 45 – 31 45 39 45 43 37 35 37 33 34 32 32 62 68 46 2 30 46 41 44 41 36 37 42 36 36 29 32 719 735 RHÖN-KLINIKUM AG | Annual Report 2023 141

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures in € ´000 Incumbent member of Board of Management Dr Gunther Karl Weiß (Member of the Board of Management) Remuneration earned in financial year Inflow1 2023 in % 2022 in % 2023 (min.) 2023 (max.) 2023 in % 2022 in % Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration2 Total payments Pension expense3 Total remuneration 500 17 517 0 517 108 625 80 3 83 0 83 17 100 500 17 517 126 643 90 733 68 2 70 17 87 13 100 500 17 517 0 517 108 625 500 17 517 250 767 108 875 500 17 517 126 643 0 643 78 3 81 19 100 0 100 500 17 517 0 517 0 517 97 3 100 0 100 0 100 1 Remuneration granted and owed in financial year. 2 The variable remuneration for 2023 is 0 €; the target agreement relating to variable remuneration was terminated in September 2023. 3 Pension expenditure includes past service cost according to IAS 19. in € ´000 Former member of Board of Management Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Total payments Severance payments Total remuneration 1 Remuneration granted and owed in financial year. Dr Christian Höftberger (Chairman of the Management Board until 31 October 2022) Remuneration earned in financial year Inflow1 2023 in % 2022 in % 2023 (min.) 2023 (max.) 2023 in % 2022 in % 0 0 0 0 0 0 0 458 7 465 115 580 1,500 2,080 22 0 22 6 28 72 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 458 7 465 158 623 1,500 2,123 22 0 22 7 29 71 100 RHÖN-KLINIKUM AG | Annual Report 2023 143

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures As at the balance sheet date, liabilities to incumbent and former members of the Board of Management in the amount of €0.0 million (previous year: €0.5 million) exist. The fees for the other statutory auditing services essentially cover certificates for hospital legislation purposes as well as for review of the separate non-financial report. As in the previous year, no tax advisory services or other services were rendered by the statutory auditor. Of the total fee (excluding VAT), no fees are attributable to other statutory auditors who are not auditors of the consolidated financial statements. 9.8 Events after the reporting date No particularly significant events have occurred since 31 December 2023 that are expected to have a material influence on the net assets, financial position and results of operations of the Group of RHÖN-KLINIKUM AG. In addition, we draw attention to one change in the Supervisory Board after the end of financial 2023: Mr. Georg Schulze notified the Company on 5 September 2023 that he is resigning his mandate as member of the Supervisory Board of the Company with effect from 31 December 2023. He thus left the Supervisory Board on 31 December 2023. By let- ter dated 12 September 2023, the trade union ver.di appointed Mr. Stefan Röhrhoff as Mr. Georg Schulze’s successor. The Local Court of Schweinfurt – by Decision of 7 December 2023 issued on application by the Board of Management with the support of the Supervisory Board – then appointed Mr. Stefan Röhrhoff, Regional Director of Ver.di, region of Hesse, health department, as member of the Supervisory Board of the Company with effect from 1 January 2024. The appointment as employee representative applies for the term of Mr. Schulze’s mandate. By letter of 13 February 2024, Mr. Kai Hankeln notified the Company that he was resigning his mandate as member of the Supervisory Board of the Company with immediate effect. No loans were granted to members of the Supervisory Board and the Board of Management. The members of the Supervisory Board and their related parties together have a shareholding interest in RHÖN-KLINIKUM AG of 0.0% (previous year: 0.0%) of total equity capital. As at 31 December 2023, the members of the Board of Management hold no (previous year: no) shares of RHÖN-KLINIKUM AG. The payments of the Supervisory Board relate to benefits due in the short term. During the 2023 reporting period, RHÖN-KLINIKUM AG received no notifications on transactions for own account by persons discharging managerial responsibilities pursuant to Article 19 of the Market Abuse Regulation (EU) No 596/2014. For the statements on share-based compensation within the meaning of IFRS 2 (cash-settled share-based payment transactions), we refer to Note 2.16.4 “Share-based payments”. 9.6 Declaration of Compliance with the German Corporate Governance Code By joint resolution of the Supervisory Board and the Board of Management of RHÖN-KLINIKUM AG of 14 December 2023, the Company made the declaration pursuant to section 161 of the German Stock Corporation Act (AktG) regarding the application of the German Corporate Governance Code in financial year 2023. It has been published on the website of RHÖN-KLINIKUM AG and thus made available to the general public. 9.7 Disclosure of the fees recognised as expenses (including reimbursement of outlays and excluding VAT) for the statutory auditors In financial year 2023, expenses resulting from fees for statutory auditors amounting to €0.9 million (previous year: €0.9 million) were incurred Group-wide. A breakdown of these fees (including outlays and excluding VAT) by service rendered is provided below: in € ´000 Fees for auditing financial statements Fees for other statutory auditing services Fees for tax advice Fees for other services Total fee 2023 2022 791 112 0 0 903 771 121 0 0 892 RHÖN-KLINIKUM AG | Annual Report 2023 145

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Corporate bodies of RHÖN-KLINIKUM AG Irmtraut Gürkan Alsbach, Dipl.-Volkswirtin (economist) PD Dr med. Thomas Pillukat Bad Neustadt a. d. Saale, MD Also a member of the Supervisory Board of: − Biolife Holding AG, Heidelberg (Deputy Chairman of the Supervisory Board) − Charité Universitätsmedizin Berlin, Berlin Christine Reißner Sülzfeld, merchant Other mandates: − Eurotransplant International Foundation, Leiden, Netherlands (Member of the Supervisory Board) − Stiftung Alice-Hospital vom Roten Kreuz zu Darmstadt, Stefan Röhrhoff Homberg, Regional Director of ver.di, region of Hesse (from 1 January 2024) Darmstadt (Member of the Board of Trustees) − Universitätsspital Basel, Basel, Switzerland (Member of the Board of Directors) − Georg-August-Universität Göttingen, Göttingen (Member of the Foundation Council) − Universitätsmedizin Göttingen, Göttingen (Deputy chairman of the Foundation Committee) Oliver Salomon Bad Berka, nurse Dr jur. Cornelia Süfke Hamburg, Legal Counsel Kai Hankeln Business address Hamburg, Chief Executive Officer of Asklepios Kliniken GmbH & Co. KGaA (until 13 February 2024) Also a member of the Supervisory Board of: − Universitätsklinikum Gießen und Marburg GmbH, Giessen − Asklepios Kliniken GmbH & Co. KGaA, Hamburg Also a member of the Supervisory Board of: − Asklepios Fachklinikum Stadtroda GmbH, Stadtroda (Chairman of the Supervisory Board) (until 13 February 2024) − MEDICLIN Aktiengesellschaft, Offenburg (until 13 February 2024) Marco Walker Business address Hamburg, Co-Chief Executive Officer of Asklepios Kliniken GmbH & Co. KGaA Dr med. Martin Mandewirth, Oberelsbach (MD, specialist in heart surgery) Facharzt für Herzchirurgie Also a member of the Supervisory Board of: − MEDICLIN Aktiengesellschaft, Offenburg − Meierhofer Aktiengesellschaft, Munich − Universitätsklinikum Gießen und Marburg GmbH, Giessen RHÖN-KLINIKUM AG | Annual Report 2023 147

CONSOLIDATED FINANCIAL STATEMENTS | Responsibility statement Responsibility statement We assure to the best of our knowledge that based on the account- ing principles to be applied the consolidated financial statements of RHÖN-KLINIKUM AG give a true and fair view of the net assets, financial position and results of operations of the Group, and that the Group Management Report presents the business performance including the business results and the situation of the Group in such a way as to give a true and fair view of the same as well as a descrip- tion of the material risks and opportunities involved in the probable development of the Group of RHÖN-KLINIKUM AG. Bad Neustadt a. d. Saale, 6 March 2024 RHÖN-KLINIKUM Aktiengesellschaft THE BOARD OF MANAGEMENT Prof. Dr Tobias Kaltenbach Dr Stefan Stranz Dr Gunther K. Weiß RHÖN-KLINIKUM AG | Annual Report 2023 149

CONSOLIDATED FINANCIAL STATEMENTS | Independent Auditor’s Report – Recognition of revenue generated from hospital services provided and revenue compensation (Erlösausgleiche) Please refer to Section 3.2 in the notes to the consolidated financial statements for information on the accounting policies applied. Disclosures on the amount of revenue can be found in the notes to the consolidated financial statements under Section 5.1. THE FINANCIAL STATEMENT RISK The revenue recognised in the Company’s consolidated financial statements relates essentially to hospital services and represents EUR 1,464.0 million. As at the reporting date, for settlement reasons revenue is based on a series of management assumptions which involve estimate uncertainties. As the budget negotiations relevant for perfor- mance often take place towards the end of the financial year, the remunerated service volumes are estimates as at the reporting date. Also at the reporting date, a revenue correction is made based on management's estimate of the change rate (case deductions) of the German Medical Review Board (Medizinischer Dienst Körperschaft des öffentlichen Rechts, MD [Medical Review Board under Public Law). Due to the complexity of the judgements described, there is the risk for the consolidated financial statements that revenue is not appropriately determined. OUR AUDIT APPROACH In order to evaluate the appropriateness of the revenue recognised as at the reporting date, we gave consideration to the Company's established processes to recognise revenue from hospital services performed and the regulatory revenue corrections required, and we verified the methodological approach of management in making the regulatory revenue corrections. In order to audit revenue recog- nition on an accrual basis, we examined the design, establishment and effectiveness of the organisational separation of the departments involved in case processing and the existence of cost assumption declarations/the treatment contract of the health insurer of the patient treated. During our audit, using (among other things) the contractual docu- mentation presented to us and other correspondence and based on a risk-oriented deliberate sample, we obtained an overview relating to the status of the various budget agreements of the hospitals in the RHÖN-KLINIKUM Group on the reporting date and the respective remunerated service volumes. For the budget negotiations which had not yet been concluded as at the reporting date, we assessed the appropriateness of the estimated budget amounts and revenue compensation. We also comprehended the management assump- tions on the service volumes to be remunerated as at the reporting date based on the detailed information provided to us. In order to assess the estimation accuracy, we compared the regulatory revenue corrections with the outcome of the negotiations with the health insurers from previous years. With respect to revenue compensation, we examined the underlying agreements in addition to the recon- ciliations of the performance statistics audited in the context of the revenue validation. In doing so, we also validated the implementation of the legal regulations. In order to audit revenue recognition on an accrual basis, we also examined revenue validation. In reference to possible corrections by the MD, we gave consideration to the process for determining the service volumes (codes applied) and for determining the relevant corrections and assessed the appro- priateness of the estimates for revenue corrections as a result of audits by the German Medical Review Board. OUR OBSERVATIONS The assumptions underlying revenue recognition are appropriate. – Recoverability of goodwill Please refer to Section 2.4.1 in the notes to the consolidated financial statements for information on the accounting policies applied and the assumptions used. Disclosures on the amount of goodwill can be found in Section 6.1 of the notes to the consolidated financial statements. RHÖN-KLINIKUM AG | Annual Report 2023 151

CONSOLIDATED FINANCIAL STATEMENTS | Independent Auditor’s Report Other Information Management and/or the Supervisory Board are/is responsible for the other information. The other information comprises the following components of the group management report, whose content was not audited: − the separate non-financial report, which is referred to in the group management report, and − the corporate governance statement, which is referred to in the group management report. The other information also includes the remaining parts of the annual report. The other information does not include the consolidated financial statements, the group management report information audited for content and our auditor's report thereon. Our opinions on the consolidated financial statements and on the group management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon. In connection with our audit, our responsibility is to read the other information and, in so doing, to consider whether the other information − is materially inconsistent with the consolidated financial statements, with the group management report information audited for content or our knowledge obtained in the audit, or − otherwise appears to be materially misstated. Responsibilities of Management and the Supervisory Board for the Consolidated Financial Statements and the Group Management Report Management is responsible for the preparation of consolidated financial statements that comply, in all material respects, with IFRSs as adopted by the EU and the additional requirements of German commercial law pursuant to Section 315e (1) HGB and that the consol- idated financial statements, in compliance with these requirements, give a true and fair view of the assets, liabilities, financial position, and financial performance of the Group. In addition, management is responsible for such internal control as they have determined necessary to enable the preparation of consolidated financial state- ments that are free from material misstatement, whether due to fraud (i.e. fraudulent financial reporting and misappropriation of assets) or error. In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern. They also have the responsibility for disclosing, as applicable, matters related to going concern. In addition, they are responsible for financial reporting based on the going concern basis of account- ing unless there is an intention to liquidate the Group or to cease operations, or there is no realistic alternative but to do so. Furthermore, management is responsible for the preparation of the group management report that, as a whole, provides an appropriate view of the Group's position and is, in all material respects, consistent with the consolidated financial statements, complies with German legal requirements, and appropriately presents the opportunities and risks of future development. In addition, management is responsible for such arrangements and measures (systems) as they have consid- ered necessary to enable the preparation of a group management report that is in accordance with the applicable German legal require- ments, and to be able to provide sufficient appropriate evidence for the assertions in the group management report. The Supervisory Board is responsible for overseeing the Group's financial reporting process for the preparation of the consolidated financial statements and of the group management report. Auditor's Responsibilities for the Audit of the Consolidated Financial Statements and of the Group Management Report Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the group management report as a whole provides an appropriate view of the Group’s position and, in all material respects, is consistent with the consolidated financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appropri- ately presents the opportunities and risks of future development, as well as to issue an auditor’s report that includes our opinions on the consolidated financial statements and on the group management report. RHÖN-KLINIKUM AG | Annual Report 2023 153

CONSOLIDATED FINANCIAL STATEMENTS | Independent Auditor’s Report We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, the actions taken or safeguards applied to eliminate inde- pendence threats. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter. Other Legal and Regulatory Requirements Report on the Assurance on the Electronic Rendering of the Consolidated Financial Statements and the Group Management Report Prepared for Publication Purposes in Accordance with Section 317 (3a) HGB We have performed assurance work in accordance with Sec- tion 317 (3a) HGB to obtain reasonable assurance about whether the rendering of the consolidated financial statements and the group management report (hereinafter the “ESEF documents”) contained in the electronic file "RhoenKlinikumAG.zip“ (SHA256 hash value: 3ef4f607e3da30ce2c228ba38fb2d1dbc2c2b64f084f07a6a4e71d b2ec31bc2b) made available and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format (“ESEF format”). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the consolidated financial statements and the group management report into the ESEF format and therefore relates neither to the information contained in these renderings nor to any other information contained in the file identified above. In our opinion, the rendering of the consolidated financial statements and the group management report contained in the electronic file made available, identified above and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format. Beyond this assurance opinion and our audit opinion on the accompa- nying consolidated financial statements and the accompanying group management report for the financial year from 1 January to 31 December 2023 contained in the "Report on the Audit of the Con- solidated Financial Statements and the Group Management Report" above, we do not express any assurance opinion on the information contained within these renderings or on the other information con- tained in the file identified above. We conducted our assurance work on the rendering of the consolidated financial statements and the group management report contained in the file made available and identified above in accor- dance with Section 317 (3a) HGB and the IDW Assurance Standard: Assurance Work on the Electronic Rendering of Financial Statements and Management Reports Prepared for Publication Purposes in Accor- dance with Section 317 (3a) HGB (IDW AsS 410 (06.2022)). Our respon- sibility in accordance therewith is further described below. Our audit firm applies the IDW Standard on Quality Management 1: Require- ments for Quality Management in Audit Firms (IDW QMS 1 (09.2022)). The Company's management is responsible for the preparation of the ESEF documents including the electronic rendering of the consolidated financial statements and the group management report in accordance with Section 328 (1) sentence 4 item 1 HGB and for the tagging of the consolidated financial statements in accordance with Section 328 (1) sentence 4 item 2 HGB. In addition, the Company’s management is responsible for such internal control that they have considered necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB for the electronic reporting format. The Supervisory Board is responsible for overseeing the process of pre- paring the ESEF documents as part of the financial reporting process. RHÖN-KLINIKUM AG | Annual Report 2023 155

SUMMARY REPORT OF RHÖN-KLINIKUM AG | Balance sheet and income statement Balance sheet and income statement BALANCE SHEET INCOME STATEMENT in € million in € million 31 Dec. 2023 31 Dec. 2022 2023 2022 ASSETS Intangible assets Property, Plant and Equipment Financial assets Fixed assets Inventories Receivables and other assets Securities, cash and cash equivalents Current assets Prepaid expenses Deferred tax assets 6.0 257.9 624.9 888.8 7.0 160.4 260.2 427.6 2.1 6.6 Revenues Changes in services in progress Other operating income Materials and consumables used Employee benefits expense Depreciation Other operating expenses Operating result Investment result Finance result Taxes 7.6 270.0 579.8 857.4 6.7 162.0 277.0 445.7 2.2 7.0 1,325.1 1,312.3 Net profit for the year Profit carried forward from previous year Net distributable profit 304.6 0.8 20.9 96.6 158.9 23.0 38.0 9.8 2.1 13.3 2.9 22.3 0.0 22.3 307.9 0.0 12.6 92.6 156.9 23.4 43.0 4.6 2.8 5.3 1.9 10.8 0.0 10.8 in € million 31 Dec. 2023 31 Dec. 2022 LIABILITIES Subscribed capital/issued capital Capital reserve Retained earnings Net distributable profit Shareholders' equity Contribution to finance fixed assets Provisions Liabilities Deferred income 167.4 589.0 201.7 22.3 980.4 14.6 31.7 297.7 0.7 167.4 589.0 201.0 10.8 968.2 10.2 44.7 289.2 0.0 1,325.1 1,312.3 The annual financial statements as at 31 December 2023 and the management report for financial year 2023 of RHÖN-KLINIKUM Aktiengesellschaft, which have been audited and certified by KPMG AG Wirtschaftsprüfungsgesellschaft with an unqualified auditor's report, will be published in the company register. Should you wish to receive a full copy, please write to the RHÖN-KLINIKUM Aktiengesellschaft. RHÖN-KLINIKUM AG | Annual Report 2023 157

FURTHER INFORMATION | Independent assurance practitioner’s report Independent assurance practitioner’s report1 To the RHÖN-KLINIKUM Aktiengesellschaft, Bad Neustadt a. d. Saale We have performed a limited assurance engagement on the combined separate non-financial report as well as the by reference qualified part “Basic Characteristics of the RHÖN-KLINIKUM Group” of RHÖN-KLINIKUM Aktiengesellschaft, Bad Neustadt a. d. Saale, (further “Company” or “RHÖN-KLINIKUM”), which consists of the sections of the Corporate-Social- Responsibility- Report (further „combined sep- arate non-financial report”) marked with a tick (√) for the period from January 1 to December 31, 2023. Management’s Responsibility The legal representatives of RHÖN-KLINIKUM Aktiengesellschaft are responsible for the preparation of the combined separate non-fi- nancial report for the period from January 1 to December 31, 2023 in accordance with §§ 315c in conjunction with 289c to 289e HGB (Handelsgesetzbuch, German Commercial Code) and with Article 8 of REGULATION (EU) 2020/852 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of June 18, 2020 on the establishment of a framework to facilitate sustainable investment and amending Reg- ulation (EU) 2019/2088 (further „EU Taxonomy Regulation“) and the supplementing Delegated Acts as well as the interpretation of the wordings and terms contained in the EU Taxonomy Regulation and in the supplementing Delegated Acts by the Company as disclosed in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. This responsibility of the legal representatives of the company includes the selection and application of appropriate methods to prepare the combined separate non-financial report and the use of assumptions and estimates for individual disclosures which are reasonable under the given circumstances. Furthermore, the legal representatives are responsible for the internal controls they deem necessary for the preparation of the combined separate non- financial report that is free from material misstatements, whether due to fraud (manipulation of the combined separate non-financial report) or error. The EU Taxonomy Regulation and the supplementing Delegated Acts contain wordings and terms that are still subject to substantial uncertainties regarding their interpretation and for which not all clarifications have been published yet. Therefore, the legal represen- tatives have included a description of their interpretation in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. They are responsible for its tenability. Due to the innate risk of diverging interpretations of vague legal concepts, the legal conformity of these interpretations is subject to uncertainty. Independence and Quality Assurance on the Part of the Auditing Firm In performing this engagement, we applied the legal provisions and professional pronouncements regarding independence and quality assurance, in particular the Professional Code for German Public Auditors and Chartered Accountants (in Germany) and the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QMS 1 (09.2022)). Practitioner’s Responsibility It is our responsibility to express a conclusion on the combined separate non-financial report based on our work performed within a limited assurance engagement. We conducted our work in the form of a limited assurance engage- ment in accordance with the International Standard on Assurance Engagements (ISAE) 3000 (Revised): “Assurance Engagements other than Audits or Reviews of Historical Financial Information”, published by IAASB. Accordingly, we have to plan and perform the assurance engagement in such a way that we obtain limited assurance as to whether any matters have come to our attention that cause us to believe that the combined separate non-financial report of the Company has not been prepared, in all material respects, in accor- dance with §§ 315c in conjunction with 289c to 289e HGB and with the EU Taxonomy Regulation and the supplementing Delegated Acts as well as the interpretation of the wordings and terms con- tained in the EU Taxonomy Regulation and in the supplementing Delegated Acts by the legal representatives as disclosed in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. 1 Our engagement applied to the German version of the combined separate non-financial report. This text is a translation of the Independent Assurance Report issued in German, whereas the German text is authoritative. RHÖN-KLINIKUM AG | Annual Report 2023 159

FINANCIAL CALENDAR DATES FOR SHAREHOLDERS AND ANALYSTS 2024 28 March Results press conference: publication of 2023 Annual Financial Report 8 May Publication of interim report for the quarter ending 31 March 2024 5 June Annual General Meeting 8 August Publication of half-year financial report as at 30 June 2024 7 November Publication of interim report for the quarter ending 30 September 2024 – analyst conference RHÖN-KLINIKUM AG DISCLAIMER The information provided in this Report does not constitute an offer or solicitation to buy shares of RHÖN-KLINIKUM AG. All reasonable care has been taken to ensure that the content of this Report was accurate on the date of publication. However, RHÖN-KLINIKUM AG accepts no warranty that all information is complete, accurate and up to date. Any investment in shares of RHÖN-KLINIKUM AG must be made on the basis of the information contained in the Company’s prospectus in its authorised form. Although as a general rule we employ the masculine form for better readability when referring to persons, this form covers all persons of the respective group, irrespective of their (social) gender and gender identity. Postal address: 97 615 Bad Neustadt a. d. Saale Germany Visitors’ address: Salzburger Leite 1 97 616 Bad Neustadt a. d. Saale Germany T. +49 (0)9771 650 F. +49 (0)9771 974 67 Internet: rhoen-klinikum-ag.com Email: rka@rhoen-klinikum-ag.com Published on 28 March 2024 This Annual Report is also available in German. Annual Report on the internet en.rhoen-klinikum-ag.com/annual-report